## 1 **Decoding Genetics, Ancestry, and Geospatial Context for Precision Health**

- 2 Satoshi Koyama M.D., Ph.D.<sup>1,2,3</sup>, Ying Wang M.D., Ph.D.<sup>1,4,5</sup>, Kaavya Paruchuri M.D.<sup>1,2,3</sup>, Md Mesbah Uddin
- 3 Ph.D.<sup>1,2</sup>, So Mi J. Cho Ph.D.<sup>1,2,6</sup>, Sarah M. Urbut M.D., Ph.D.<sup>1,2</sup>, Sara Haidermota B.S.<sup>1,2</sup>, Whitney E.
- 4 Hornsby Ph.D.<sup>1,2</sup>, Robert C. Green M.D., M.P.H.<sup>3,7,8</sup>, Mark J. Daly Ph.D.<sup>4,5,9,10</sup>, Benjamin M. Neale Ph.D.<sup>1,4,5</sup>,
- 5 Patrick T. Ellinor M.D., Ph.D.<sup>1,2,3</sup>, Jordan W. Smoller M.D., Sc.D.<sup>3,11,12</sup>, Matthew S. Lebo Ph.D.<sup>3,13,14</sup>,
- 6 Elizabeth W. Karlson M.D., M.S.<sup>3,13,15</sup>, Alicia R. Martin Ph.D.<sup>1,4,5,\*</sup>, and Pradeep Natarajan M.D., M.M.Sc<sup>1,2,3,\*</sup>
- 7 1. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA<br>8 2. Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, B
- 8 2. Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA<br>9 3. Department of Medicine, Harvard Medical School, Boston, MA, USA
- 9 3. Department of Medicine, Harvard Medical School, Boston, MA, USA<br>10 4. Analytic and Translational Genetics Unit, Massachusetts General Ho
- 10 4. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA<br>11 5. Stanley Center for Psychiatric Research. Broad Institute of MIT and Harvard. Cambridge. MA.
- 11 5. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 12 6. Integrative Research Center for Cerebrovascular and Cardiovascular Diseases, Yonsei University College of Medicine, 13 Seoul, Republic of Korea
- 14 7. Department of Medicine (Genetics), MassGeneralBrigham, Boston, MA, USA<br>15 8. Broad Institute and Ariadne Labs, Boston, MA, USA
- 15 8. Broad Institute and Ariadne Labs, Boston, MA, USA<br>16 9. Institute for Molecular Medicine Finland (FIMM), Finl
- 16 9. Institute for Molecular Medicine Finland (FIMM), Finland<br>17 10. University of Helsinki. Helsinki. Finland
- 17 10. University of Helsinki, Helsinki, Finland<br>18 11. Psychiatric and Neurodevelopmental G
- 18 11. Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital,<br>19 **19** Boston, MA, USA Boston, MA, USA
- 20 12. Center for Precision Psychiatry, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA<br>21 13. Mass General Brigham Personalized Medicine, Cambridge, MA, USA
- 13. Mass General Brigham Personalized Medicine, Cambridge, MA, USA<br>22 14. Department of Pathology, Brigham and Women's Hospital, Boston, M.
- 22 14. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
- 23 15. Division of Rheumatology, Inflammation and Immunity, Department of Medicine, Brigham and Women's Hospital., Boston, MA, USA
- 25 \* A.R.M. and P.N. jointly supervised this work.
- 26 Please address correspondence to:
- 27 Alicia R. Martin, Ph.D.
- 28 185 Cambridge Street
- 29 Boston, MA 02114
- 30 armartin@broadinstitute.org
- 31 Pradeep Natarajan, M.D., M.M.Sc
- 32 185 Cambridge Street
- 33 Boston, MA 02114
- 34 pnatarajan@mgh.harvard.edu
- 35 Figures 5
- 36 Supplemental Figures 10
- 37 Supplemental Tables 7
- 38 Supplemental Information (9 Figures)

#### **Abstract**

- Mass General Brigham, an integrated healthcare system based in the Greater Boston area of
- Massachusetts, annually serves 1.5 million patients. We established the Mass General Brigham
- Biobank (MGBB), encompassing 142,238 participants, to unravel the intricate relationships among
- genomic profiles, environmental context, and disease manifestations within clinical practice. In this
- study, we highlight the impact of ancestral diversity in the MGBB by employing population genetics,
- geospatial assessment, and association analyses of rare and common genetic variants. The population
- structures captured by the genetics mirror the sequential immigration to the Greater Boston area
- throughout American history, highlighting communities tied to shared genetic and environmental factors.
- Our investigation underscores the potency of unbiased, large-scale analyses in a healthcare-affiliated
- biobank, elucidating the dynamic interplay across genetics, immigration, structural geospatial factors,
- and health outcomes in one of the earliest American sites of European colonization.

#### **Introduction**

Determinants of health include a complex interplay of sociodemographic, structural, genetic, and environmental factors that are also contextually dependent on time and geography. Disease risk prediction models and therapeutic paradigms are largely agnostic to many of these important features yet are intended for broad use. Such training datasets often lack the breadth and depth of information and the inherent diversity across features required for equitable applications. The United States populace is highly diverse, marked by complex migration patterns and dynamic social constructs and represents multilevel health contributors. For example, it is widely recognized that the prevalence of diseases is closely linked to individual or neighborhood social deprivation, which further varies across 60 smaller domains and regions<sup>1,2</sup>. Furthermore, these determinants differentially contribute to health outcomes depending on local factors<sup>3,4</sup>.

Contemporary healthcare-associated biobanks represent a new opportunity to discover novel determinants of health and augment translation to clinical care. Such endeavors represent a recent 64 collaborative synergy of large-scale population-based- $5-8$  and local healthcare- biobanks $9-13$ . Understanding how DNA sequence variation tracks contemporary and historical population demographics can provide insights on differential disease burdens. For example, rs5742904 (c.10580G>A, p.Arg3527Gln) in *APOB*, a founder pathogenic mutation for familial hypercholesterolemia has significantly higher allele frequency in Old Order Amish people. It substantially explains the 69 increased risk for coronary artery atherosclerosis in this population<sup>14,15</sup>. Important insights related to genetic variations and clinical outcomes may often require profiling diverse populations. For example, the discovery of the association between disruptive variants in *PCSK9*<sup>16,17</sup> and lower low-density 72 lipoprotein cholesterol in the African population, where these variants are prevalent, facilitated drug development. As another instance, *G6PD* deficiency18 was recognized as a prevalent hemolytic disease in Sub-Saharan Africa. Studying diverse populations across a spectrum of diseases is crucial to assess the penetrance of disease-associated monogenic alleles<sup>19</sup> and polygenic models<sup>20</sup>.

Recent analyses of biobanks in the United States have uncovered the complex genetic structure of Hispanic and/or Latinx groups tracing their origins to the Americas<sup>9,12</sup>. In these efforts, it has been demonstrated that the fine genetic structure within biobanks can identify varying disease risks by capturing both ancestral and social structures, thereby contributing to the advancement of personalized medicine. Separately, recent advances in data size and methodology have enabled us to precisely characterize the complex population dynamics associated with multiple colonization and admixture 82 events<sup>21-23</sup> However, the interplay across these features, or their interaction with large-scale genetic association studies using whole-genome imputed or sequenced data, remains understudied.

**Service State State** 

- The New England region represents among the earliest European colonization of the United States with
- sequential ongoing migration from diverse groups. In this study, we examined the genetic variation
- across New England coupled with sociodemographic, clinical, and environmental/geospatial factors in
- the Mass General Brigham Biobank (MGBB). By applying a network-based clustering algorithm with
- newly generated reference dataset, we established fine genetic clusters with subcontinental resolution
- within MGBB. These clusters exhibited distinct genetic properties, geographic distributions,
- socioeconomic statuses, and disease risks. In combination with rare and common variant genetic
- association analyses, we gained further insights into the different disease risks among these
- populations. Collectively, this study highlights the power of large-scale, unbiased analyses within a
- healthcare-based biobank to understand the complex interplay between genotypes and phenotypes,
- paving the way for increasingly personalized interventions.

#### **Results**

#### **Participant recruitment and Electronic Health Record (EHR) based phenotyping**

- Since 2010, 142,238 individuals within the Mass General Brigham (MGB) network, the largest
- healthcare system in Massachusetts, have consented to participate in the MGBB as of May 11, 2023
- (Figure 1a, Supplemental Information Figure 1, Supplemental Table 1). Among participants, 99.5% (n =
- 141,519) consented to re-contact. 56.8% of participants are female (n = 80,851, Figure 1b). Median
- [interquartile range; IQR] age at consent was 51 [35 63] years for female participants and 58 [43 68]
- years for males. Self-reported races were 84.4% White, 4.5% Black, and 3.0% Asian. Self-reported
- ethnicities were 86.6% non-Hispanic and 2.44% Hispanic (Supplemental Information Figure 2). The
- participants are primarily cared for at the two flagship MGB hospitals, both located in Boston, MA, and
- their associated clinics Massachusetts General Hospital (MGH) and Brigham and Women's Hospital
- (BWH, Figure 1c). The biobank data is interlinked with EHRs with phenotype data across the MGB
- network, as well as notable specialty centers in Boston, MA including the Mass Eye and Ear Institute
- (MEEI) and Dana-Farber Cancer Institute (DFCI). To generate systemically annotated
- prevalent/incident outcomes, we extracted International Classification of Diseases codes, Nineth (ICD9)
- 110 and Tenth (ICD10) revisions, from the EHR and mapped them to PheCodes<sup>24</sup>. We identified 1,577 of
- 1,860 possible PheCodes with at least one event (Figure 1d). Participants were followed for a median
- [IQR] of 4.3 [2.5 6.0] years after inclusion to MGBB with a median of 12 [5 25] incident events per

person.

#### **Fine-scale clustering of genetic ancestry in MGBB**

Extending beyond traditional low-dimensional projections of continental ancestry from genome-wide data, we utilized high-dimensional principal components (PCs) to achieve greater granularity. Using genome-wide genotyping arrays, we genotyped 53,306 participants in the MGBB. By employing the top genetic PCs and a network-based clustering approach<sup>25</sup>, we identified 30 data-driven distinct ancestral clusters (Figure 2a, 2b, and 2c, Figure S1, Supplemental Table 2). The largest cluster (cluster 0, ordered by sample size) includes 11,875 (22.3%) MGBB individuals. The smallest (cluster 29) includes only one MGBB participant as well as 27/27 reference Sardinian individuals from Human 122 Genome Diversity Project (HGDP)<sup>26</sup>, suggesting the origin of this individual. As such, unsupervised

- 123 clustering with diverse populations from the 1000 Genomes Project Phase 3  $(1KG)^{27}$  and HGDP
- 124 reference panels<sup>28</sup> allowed us to infer the genetic similarity between these clusters and populations

worldwide in an unbiased manner.

Cluster 0 was genetically similar to the Western European populations in the reference dataset (CEU

[Utah residents with Western or Northern European ancestry] and GBR [British from England or

Scotland] in 1KG, French and Orcadian in HGDP, Figure S2). In addition to the cluster 0, we identified

eight distinct 1KG+HGDP-EUR-like clusters that cluster with Italian, Russian, Spanish, Adygei, Finnish,

Basque, and Sardinian ancestries reflecting known patterns of migration to the Greater Boston Area.

We also identified two distinct 1KG+HGDP-AMR-like clusters (cluster 5 enriched with PUR [Puerto

Rican in Puerto Rica], cluster 8 with Colombian, Maya, PEL [Peruvian in Lima, Peru], Pima, CLM

[Colombian in Medellín, Colombia], MXL [Mexican ancestry in Los Angeles, CA]), four African-like

clusters (cluster 6 enriched with African Caribbean in Barbados and African Ancestry in Southwest USA,

cluster 17 specific to Nigerian Africans [Esan in Nigeria, Yoruba in Ibadan, Nigeria], cluster 22 specific

to Kenyan Africans [Bantu and Luhya in Webuye, Kenya], and cluster 18 with other Western Africans

[Mandinka, Mende people in Sierra Leone, Gambian in Western Divisions in the Gambia]), and three

East Asian-like clusters (cluster 19 specific to Japanese, cluster 20 specific to Uygur, and cluster 9 with other East Asians). We identified a single large cluster (cluster 10) enriched in South Asian reference

populations, however, Hazara and Kalash populations formed distinct clusters.

Even with a diverse reference dataset, eight clusters comprising 9,874 (18.8%) MGBB individuals did 142 not have enrichments of specific populations from the reference dataset. Among these unannotated

clusters, seven clusters (4,7,11,13,14,15, and 21) exhibited genetic similarities to 1KG+HGDP-EUR

144 populations. We calculated pairwise Fixation Index  $(F_{ST})$  values among clusters, and then constructed a

phylogenetic tree of the clusters. The observed population differentiation between clusters further

corroborates the ancestral relationships but notable distinctions from continental populations and residents in New England (Figure S3a).

 We also conducted ADMIXTURE<sup>29</sup> analyses to infer continuous population structures within these genetic clusters, many of which show similar patterns of structure across increasing numbers of ancestral components (Figure S3b). Using cross validation, ten was the best fit number of components (Supplemental Information Figure 3). We identified two 1KG+HGDP-EUR-like components (distinguished by components 4 and 9). The component 4 was most enriched in the Finnish-like cluster (cluster 24), and relatively enriched in northern European-like clusters (0, 1, and 3) more than the southern European-like clusters (2, 12, and 14). In contrast, the component 9 was enriched in the southern European-like cluster. We also observed a third component included in the European ancestries (component 3). This component 3 is prominent in the Kalash (Indo-European in northwest Pakistan) and other Pakistani reference populations. While this was enriched in southern European-like clusters, it was more enriched in un-annotated European-like genetic clusters 4, 7, 11, 13, and 21 than other annotated European genetic clusters, possibly consistent with Middle Eastern origins as this

- 160 group is poorly represented in reference datasets.
- 161 Cluster 4 the 5<sup>th</sup> largest cluster in this study (n = 3,514) is one of such un-annotated European

162 clusters. By comparison of allele frequencies between gnomAD ancestries and our dataset, we found

- 163 that cluster 4 has allele frequencies most similar to the Ashkenazi Jewish reference population
- (Supplemental Table 3). We also observed strong enrichment of skin neoplasms and inflammatory
- bowel diseases which were previously noted to be enriched in known Ashkenazi cohorts (Figure S4).
- We also observed significant enrichment of Ashkenazi Jewish founder mutations (e.g., *APC* c.3920T>A,
- p.Ile1307Lys, *BRCA1* c.68\_69del, p.Glu23fs, *BRCA1* c.5266dup, p.Gln1756fs, *BRCA2* c.5946del,
- 168 p.Ser1982fs)<sup>31,32</sup> in this genetic cluster (Figure S5). We also observed enrichments of these founder
- mutations in un-annotated European clusters 11 and 14 suggesting close genetic relationships between
- these clusters to the Ashkenazi-like cluster 4. In addition to the European-like components, we also
- identified two different components (components 5 and 7) enriched in the East Asian clusters. One of
- these components (component 5) was also observed in the Finnish-like cluster which is consistent with
- 173 previous observations  $33-36$ .

#### **Effective population size of ancestry clusters in the Greater Boston area**

To characterize the ancestral clusters observed in the MGBB, we estimated the historical transition of effective population size of each cluster using genome-wide genetic data (Figure S6). We conducted IBD-based estimation for effective population sizes (*N*e). Our results were consistent with some prior results conducted outside of the U.S. For example, we replicated previously described bottleneck event in Ashkenazi-like population (cluster 4). The lowest *N*e was estimated to be 1,170 (95% CI = 1,100 –  $-$  1,270) individuals at 28 generations ago<sup>37</sup>. We observed similar bottleneck events in clusters 11 and 14 around the same generation (minimal *N*e was 4,570 [4,210 – 5,030] in cluster 11 and 32,600 [30,700 – 35,900] in cluster 14) consistent with the aforementioned sharing pattern of Ashkenazi founder mutations with cluster 4. The largest genetic cluster 0 indicates a population bottleneck occurring approximately 12 generations ago. This timeframe coincides with the initial colonization of the Boston area by British settlers. Intuitively, this event is not evident in the British population from the UK Biobank 186 (UKBB) here or in previous studies<sup>38,39</sup> (Supplemental Information Figure 4), suggesting a unique founder event among British Americans due to colonization. We also observed a significant bottleneck event in the Admixed American populations, specifically in clusters 5 and 8, with a pronounced magnitude in the Puerto Rican-like cluster 5 (minimal *N*e was 11,300 [11,100 – 11,600]). However, we did not observe such bottlenecks for other clusters potentially reflective of more continuous migration.

#### **Genetic clusters, geographic and socioeconomic factors, and disease risks**

We used geospatial scan statistics to understand the geographical structure of MGBB ancestry clusters. We observed 22 statistically significant regions of geographical enrichment among 13 genetic clusters

- in smaller than 4-km radius areas. We observed distributions of genetically inferred clusters
- recapitulating colonization histories into the Greater Boston Area (Figure 3a). One example of strong
- enrichment was observed in the southern area (Roslindale / Mattapan / Dorchester and separately
- Roxbury) by cluster 6 (ACB [African Caribbean in Barbados] and ASW [African ancestry in Southwest
- 198 U.S.], expected number 105 and observed number 725,  $P < 1 \times 10^{-17}$ ). Another strong enrichment is
- observed northern of Boston (Charlestown / Chelsea) by cluster 5 (PUR [Puerto Rican in Puerto Rico],
- 200 expected number 180 and observed number 624,  $P < 1 \times 10^{-17}$ ) in addition to Boston's South End
- extending to Roxbury / Hyde Park / Jamaica Plain. We also observed enrichment of Ashkenazi Jewish-
- like (cluster 4) and East Asian-like clusters (cluster 9) in areas seeded by early founding communities,
- such as Back Bay / Brookline / Cambridge (cluster 4) and Allston (cluster 9), respectively.

The western European-like clusters cluster 0 and cluster 1 were similar in conventional PC space 205 (Figure S1) and ADMIXTURE analysis (Figure S3b)<sup>29</sup>, but well differentiated by network-based

- 
- clustering (Figure 2a) as well as geospatially. The CEU/GBR-like cluster 0 was enriched in central
- areas of the Boston (Beacon Hill) and Cambridge (Harvard Square), representing the earliest sites of
- British colonization. Cluster 1 (Orcadian-like, tagging northern populations of the British Isles including
- those hailing from Scotland and Ireland) is enriched in two different geographical locations, including
- Chelsea and South Boston, where secondary colonization occurred. These different geographical
- enrichments of cluster 0 versus cluster 1 reflect the distinct histories of these two similar, but distinct
- 212 genetic European ancestries.
- Socioeconomic status was correlated with both genetic ancestry as well as ancestral geographic
- distributions<sup>1</sup>. Using geocoded location information for each participant in our study, we calculated a
- Social Deprivation Index (SDI, ranged from 0 to 100, higher SDI indicating greater deprivation) for each
- participant and associated this with healthcare outcomes (Figure S8, Supplemental Table 4). The
- distributions of SDI widely differed across genetic ancestries (Figure S7a). Specifically, Cluster 6
- (enriched with African Caribbean in Barbados like population) exhibited the highest level of deprivation,
- with a median [IQR] SDI score of 83 [52 94]. Conversely, Cluster 4 (Ashkenazi Jewish-like) had the
- lowest deprivation, as indicated by a median [IQR] SDI score of 22 [8 45].

221 To systemically identify the associations between socioeconomic status and disease risk in MGBB, we 222 associated SDI with phenome-wide outcomes captured by EHRs, adjusting for genetic ancestries. We

found SDI was significantly associated with 400 out of 1,564 phenome-wide outcomes (Bonferroni *P* <

- $224$  0.05/1,564 = 3.2 x 10<sup>-5</sup>, Figure 3b). Greater SDI was generally associated with increased disease
- 225 prevalence and incidence (385 out of 400). The strongest SDI-associated PheCodes was with Tobacco
- 226 use disorder (odds ratio; OR [95%CI]) per one standard deviation (SD) of SDI was 1.54 [1.48 1.60],
- 227 followed by Mood disorders ( $OR = 1.26$  [1.23 1.30]), and Depression ( $OR = 1.26$  [1.23 1.30]). As
- 228 represented by these examples, we observed greater risks for Mental disorders, followed by
- 229 Uncharacterized Symptoms, Respiratory, and Circulatory systems per PheCodes categories,
- 230 respectively (Figure 3c). However, prostate (OR  $0.85$  [0.80 0.90]) and breast (OR  $0.89$  [0.84 0.95]),
- 231 cancer had significant/nominal negative associations with SDI (Figure 3b).
- 232 Using coronary artery disease (CAD) as an example of a common complex condition, we identified a
- 233 significant association between SDI and CAD independent from clinical and genetic risk. The
- 234 association remained significant even after adjustments for clinical risk score (Pooled Cohort Equation,
- 235 PCE)<sup>40,41</sup>, and polygenic risk score<sup>42</sup> (PRS, OR<sub>1SD-SDI</sub> = 1.26 [1.17 1.35], OR<sub>1SD-PCE</sub> = 1.73 [1.65 –
- 236 1.81], OR<sub>1SD-PRS</sub> 1.24 [1.13 1.36], in the multivariate model adjusted by the first ten genetic PCs,
- 237 Figure S7).

#### **Exome Sequencing in MGBB**

- Using high-coverage whole exome sequencing in the same group of individuals, we systemically
- 240 identified rare coding variants in MGBB. There were significant differences in variant distributions
- 241 across clusters. For instance, the Ashkenazi-like cluster 4 had fewer singleton variants (median  $[IQR] =$
- 138 [126 152] for cluster 4, and 489 [408 566] for others). In contrast, there were significantly more
- singletons in clusters 11 and 14, even though they are closely related to cluster 4 (320 [294 361] and
- 400 [372 436], respectively, Supplemental Information Figure 5).
- We identified median 15 [12 18] rare (Minor allele frequency, MAF < 0.01), high-confidence predicted
- loss-of-function (pLOF) variants per participant (Figure 4a). The largest number of pLOF variants were
- observed in African-like clusters (23.5 [20.25 26.0] in cluster 22, 21 [19 22] in cluster 26, 21 [17 –
- 24] in cluster 17, 20 [17.0 23.0] in cluster 6). The Northern European-like clusters 1 and 0 had the
- fewest pLOFs (13 [11.0 16.0] in cluster 1 and 14 [12 17] in cluster 0 and 3). We also identified 1,425
- individuals (2.8% of total population) with at least one rare autosomal pLOF homozygous genotype
- across 761 genes.
- We next explored established pathogenic variants (Figure 4b) in MGBB. 2.6% (1,318/50,625) of
- participants carry a potentially actionable pathogenic/likely pathogenic variant per American College of
- 254 Medical Genetics and Genomics secondary findings guideline (ACMG SF, version 3.1)<sup>43,44</sup>. These
- included 6 homozygotes (*TP53*, *LDLR, 4 MUTYH*), and 7 potential compound heterozygotes (2 *BTD*, 3
- *MUTYH*, *ATP7B*, and *GAA*). Across genetic clusters, we observed substantial differences in the
- 257 prevalence of these pathogenic variants (Figure 4c). The highest rate of actionable findings (> 4%) was
- observed in clusters 11 and 4 despite generally having the lower prevalence of very rare variants.
- Conversely, non-European clusters generally showed lower rates for annotated actionable variants.
- Considering higher number of alternate allele-counts in the non-European clusters, the genetic
- diagnostic rate was significantly lower in non-European populations (Figure S9). Namely, pLOF variants
- 262 on ACMG SF v3.1 genes found in African and East Asian clusters have significantly lower likelihood of
- being annotated with a high-quality (more than equal two-stars) pathogenic/likely pathogenic annotation
- 264 in comparison to the European participants (OR<sub>AFR</sub> 0.27 [0.18 0.41] and OR<sub>AMR</sub> and 0.48 [0.35 0.65],
- tested by Fisher's exact test), at least partly related to the underrepresentation of causative variants
- 266 recurrently observed in non-European groups in the ClinVar<sup>45,46</sup> database.
- To understand the clinical consequences of rare coding variants, we performed exome-wide and
- 268 phenome-wide association study (PheWAS) across 1,454 PheCodes and 14,912 genes. We did not
- 269 find substantial evidence of inflation in the test statistics (median Lambda  $GC<sub>1.0%</sub>$ </sub> 0.89 [0.86– 0.93] for
- AFR, and 0.90 [0.87 0.93] for AMR, 1.02 [0.99 1.05] for EUR, Supplemental Information Figure 6a).

- 271 We identified 51 significant associations  $(P < 1.8 \times 10^{-9}$ , 0.05/28,035,307 tested phenotype-transcript
- 272 pairs, Supplemental Table 5) in the burden of rare pLOF and deleterious missense variants with 14
- 273 genes, which included 8 ACMG SF v3.1 genes across 45 clinical outcomes (Figure 4d). In addition to
- 274 the genes associated with known traits, we found significant associations between *PTEN* deleterious
- 275 variants and increased risk for secondary hypothyroidism. This link was not described by previous rare
- 276 variant targeted analysis<sup>47,48</sup> while *PTEN* deleterious variants have been known to be causal for
- 277 hamartoma syndrome including thyroid cancers and abnormalities<sup>49,50</sup>. Nevertheless, we highlight
- 278 numerous persistent risk signals from known Mendelian mechanisms of disease in MGBB.

#### **Genome-wide PheWAS in MGBB**

To further explore the relationship between genotype and phenotype in MGBB, we conducted a comprehensive genome-wide PheWAS using ICD code-based PheCodes. We associated over 20 million common variants in African, European, and Admixed populations, which were imputed using the 283 TOPMed imputation reference panel,<sup>51</sup> with 1,461 PheCodes. Similar to the rare variant burden test, we observed calibrated test statistics overall (median Lambda GC [IQR] were 0.98 [0.95 – 1.00] for AFR, 0.97 [0.93 – 1.00] for AMR, 1.02 [0.99 – 1.03] for EUR, Supplemental Information Figure 6b). We

- 286 identified 111 associations that reached genome-wide significance ( $P < 5 \times 10^{-8}/3.048 = 1.6 \times 10^{-11}$ ).
- Figure 5a, Supplemental Table 6), including 3 African and 1 AMR associations. We refined the
- prognosis of identified known low-frequency monogenic variants. For instance, we observed that the
- variant rs6025 (*F5,* c.1601G>A, p.Arg534Gln; Factor V Leiden) is strongly associated with Congenital
- deficiency of other clotting factors, including factor VII (OR [95%CI] = 11.56 [9.37 14.27], *P* = 3.6 ×
- $10^{-68}$ . Similarly, rs113993960 a pathogenic variant in *CFTR* (c.1521 1523del, p.Phe508del) is
- 292 associated with Cystic fibrosis (OR 14.67 [11.66 18.44],  $P = 2.4 \times 10^{-87}$ ).
- Some of these variants exhibited a pronounced recessive effect on the phenotype. A prime example is the variant rs72660908, which is associated with Rhesus isoimmunization in pregnancy (Figure 5b).
- This medical condition exemplifies recessive inheritance resulting from the deletion of the *RHD* gene.
- 296 As anticipated, the OR for heterozygotes was not significant (OR $_{\text{Hetero}}$  = 1.18 [0.53 2.7]) compared to
- 297 the strong effect observed in homozygotes ( $OR_{Homo} = 24.3$  [14.6 43.1], Figure 5c). Recent large-scale
- 298 sequencing analysis of structural variants<sup>52</sup> identified high linkage disequilibrium (LD) between
- 299 rs72660908 and a large deletion affecting  $RHD$  ( $R^2 > 0.99$ ), which we support by strong expression
- 300 quantitative trait loci (eQTL) effect of rs72660908 on *RHD*<sup>53</sup> (Figure 5d) and low coverage by exome
- sequencing in the MGBB (Supplemental Information Figure 7). We also observed a significant enrichment of cases among individuals who were homozygous for rs72660908, with 127 out of 156 cases having the G/G genotype at this locus. As previously reported, individuals with the homozygous
- alternate allele for rs72660908 have a recessive inheritance pattern in European ancestry populations, but the frequency fluctuates among clusters (17% in cluster 0 and 9% in cluster 4, Figure 5e), and we observed very few copies in AFR/EAS populations.

Another noteworthy example is the association between rs73404549 and sickle cell anemia in the AFR population. This variant is in strong LD with rs334 (*HBB* c.20A>T, p.Glu7Val, HbS), a well-established pathogenic variant for sickle cell anemia. Despite high medical relevance, rs334 was not included in the TOPMed reference panel. We re-evaluated the impact of rs334 using exome sequencing data on sickle cell anemia and clinical red blood cell counts. rs334 showed stronger and more penetrant effect size for

- sickle cell anemia than imputed rs73404549 (β<sub>rs334</sub> = 4.14 ± 0.25,  $P_{rs334}$  = 5.9 × 10<sup>-94</sup>, β<sub>rs73404549</sub> = 3.05 ±<br>313 0.22,  $P_{rs73404549}$  = 4.4 × 10<sup>-46</sup>) with 14 homozygotes for rs334 and a penetrance rate of 79% (
- 0.22,  $P_{rs73404549} = 4.4 \times 10^{-46}$ ) with 14 homozygotes for rs334 and a penetrance rate of 79% (Figure
- 314 S10a). Additionally, we noted another missense variant rs33930165 in *HBB* (*HBB* c.19G>A, p.Glu7Lys,
- 315 HbC) previously shown to confer malarial resistance without sickle cell anemia. We found 5
- 316 participants with sickle cell anemia heterozygous for both HbS or HbC with significantly lower red blood
- 317 cell counts compared to heterozygotes for either genotype (Figure S10b).

#### **Discussion**

In this study, we conducted multidimensional investigations into the structure of a modern healthcare-based biobank based at one of the earliest sites of durable European colonization. We show how expanded immigrant communities in the U.S. often exhibit genetic similarities to contemporary continental populations and reflect common bottlenecks. However, we also observe distinct bottlenecking effects of early colonization and patterns of admixture, and identify populations not well represented in reference datasets. Using geospatial indices, genetic ancestries, and phenome-wide outcome data, we described the architecture of diseases associated with regional socioeconomic factors such as area-level poverty, education level, single parent households, living in rented housing units or overcrowded housing units, living without a care or unemployment<sup>54</sup>. We further leverage rich genotyping and phenotyping to clarify several clinically relevant genetic associations complementing clinical and environmental features. This work advances an overall goal of comprehensively quantifying heterogeneous health determinants that uniquely vary across diverse communities in the U.S.

Leveraging population genetics, we delineated the complex ancestral components present within the 332 Boston area. While our findings align well with prior studies on nationwide cohorts<sup>22,23,38,39</sup>, our research offers further granular insights into the individual-level ancestral histories of the participants, including lifestyle, genetic, and social risk factors associated with the diseases. We used genetic variation to explore the dynamic interplay of migration, expanded colonization sites, and geographic and community variation, aiming to study how social deprivation influences health, independent of the clinical and genetic risk factors. With distinctions from continental level ancestral histories, the complex history of communal- and individual-level factors can be uniquely mapped by healthcare-associated biobanks to uncover novel important drivers of health.

 Area-defined SDI improved prediction performance when incorporated into existing clinical<sup>55,56</sup> and 341 genetic risk stratification models<sup>57,58</sup> for common complex diseases. In this study, by integrating large scale EHR data and geographical information, we systemically assessed the impact of SDI on Phenome-wide scale across diverse ancestries and drew several clinical implications. First, our systemic assessment suggests that although SDI is a significant contributor to a wide range of diseases, the impacts of SDI are significantly varied across disease domains. For example, while mental and cardiopulmonary diseases are more prevalent among individuals experiencing social deprivation, cancers and congenital diseases are observed almost equally, irrespective of deprivation status. Furthermore, SDI is differentially yet ubiquitously associated with a wide array of health outcomes across various genetic ancestral groups. Finally, although the effect of SDI persisted across various

genetic clusters, the varying magnitude of association suggests an interaction between social deprivation and genetic factors as previously suggested<sup>59,60</sup>.

In addition to enabling detailed disease modeling, healthcare biobanks are unique and powerful resources for exploring rare genetic conditions or disease outcomes. First, we identified individuals carrying actionable variants, as defined by a curated database. However, these individuals are predominantly of specific European ancestries, suggesting a bias against non-Europeans in reference datasets, potentially resulting from disparities in clinical genetic testing<sup>19,61</sup>. Using an unbiased genomic scan, our study uncovered several significant associations, which may further refine prognosis within healthcare settings. Furthermore, we confirmed a penetrant association between an upstream variant 359 of the *RHD* gene and Rhesus isoimmunization during pregnancy<sup>13,62</sup>, while also clarifying varied prevalence across diverse communities. Bringing these findings together, we highlight that healthcare biobanks, compared to general population-based biobanks, are enriched with uncommon outcomes, and associated genetic variations, thereby offering an ideal environment to study clinically pertinent scenarios.

Nevertheless, our study warrants several limitations. First, most of our enrollment occurred in tertiary hospitals. While this enabled us to include patients with rare and more severe conditions, the

366 prevalence may not reflect the general population due to inclusion bias as previously described<sup>63</sup>.

Second, MGBB participants are centralized in the greater Boston area of Massachusetts, which reflects

the geographic location of the two main hospitals of the MGB health system. Communal and geospatial

characteristics are likely to vary in other New England regions and more broadly across the U.S.

Moreover, while our study provides detailed insights into European populations, the resolution for non-

European populations is less robust due to limited sample sizes, reflecting the demography of the included region.

In conclusion, by utilizing a population genetics, we discerned specific ancestral clusters within the MGBB. These clusters reflect the colonization histories of the Greater Boston area and exhibit distinct genetic characteristics and disease susceptibilities. Individual-level clinical and lifestyle risk factors in combination with community context, structural factors, and genetic variation advance disease modeling toward precision medicine initiatives.

#### **Methods**

#### **Patient recruitment in MGBB and study protocols**

MGBB, previously known as Partners Biobank, is an integrated research initiative based in Boston, Massachusetts. It collects biological samples and health data from consenting individuals at Massachusetts General Hospital, Brigham and Women's Hospital, and local healthcare sites within the MGB network<sup>64</sup>. This repository of samples and data supports researchers aiming to decipher disease 384 mechanisms, enhance personalized medicine, and innovate therapeutic solutions. Since July 1<sup>st</sup>, 2010, the MGBB has enrolled 142,238 participants, and extracted DNA from 88,665 participants' samples (62.3%). All participants provided written/electronic informed consent for broad biological and genetic research. The study protocol to analyze MGBB data was approved by the Mass General Brigham Institutional Review Board under protocol number 2018P001236. The study protocols to analyze UKBB data was approved under protocol number 2021P002228 and performed under UKBB application number 7089.

#### **Genotype quality control and imputation**

53,306 individuals were genotyped by Illumina Global Screening Array (Illumina, CA) in four batches (13,140 in the 1<sup>st</sup> batch, 11,649 in the 2<sup>nd</sup> batch, 5,976 in the 3<sup>rd</sup> batch, and 22,541 in the 4<sup>th</sup> batch). 394 Genotypes were called using the Z-call software<sup>65</sup>. After genotype calling, we conducted quality control with the following steps. We re-aligned genotyping probes to the GRCh38 reference genome using the blast software<sup>66</sup> and extracted probes with perfect- unique match. We removed indels and multiallelic 397 sites and removed variants with high missingness ( $> 2\%$ ) and low minor allele counts ( $\leq$  2). After genotype quality control, we estimated continental level ancestry using the 1KG dataset. We extracted common, high-quality SNPs (missingness < 1%, MAF > 1%) across MGBB and the 1KG dataset. After pruning SNPs, we computed SNP weights for genetic principal component using the 1KG dataset. Then, we projected MGBB participants into the same principal component space using 10 PCs. Using genetic PCs in 1KG dataset as a feature matrix, we trained a K-nearest neighbor model for population assignment (AFR, AMR, EAS, EUR, and SAS) to assign population labels to MGBB participants. With these inferred labels, we calculated Hardy Weinberg disequilibrium for each population and removed 405 variants with  $P < 1 \times 10^{-6}$ . Finally, we compared the allele frequency in these populations with gnomAD allele frequency, then removed variants with deviation from ancestry specific gnomAD allele frequency (Chi-square value > 300). These quality control procedures were done by genotyping batch. We took the intersection of the variants in these four batches and generated dataset for imputation. Using the same set of variants, we imputed the genotypes by TOPMed imputation server<sup>67</sup>. We used TOPMed multi-ancestry imputation reference panel (TOPMed r2 panel) including 97,256 reference samples and

- $308,107,085$  variants. Pre-phasing was carried out by Eagle software<sup>68</sup>, and imputation was conducted
- 412 by Minimac4 software<sup>67,69</sup>. After the imputation, we merged all the four batches by vcftools<sup>70</sup> and
- 413 converted to bgen file by PLINK2 software (9 Jan 2023)<sup>71</sup> for the downstream analysis.

#### 414 **Exome sequencing and quality control**

Exome sequences were performed by on Illumina NovaSeq instruments (Illumina, CA) with a custom exome capture kit (Human Core Exome, Twist Bioscience, CA), with a target of at least 20x coverage at > 85% of target sites. Alignment, processing, and joint calling of variants were performed using the 418 Genome Analysis ToolKit (GATK, version v4.1)<sup>72</sup> following GATK best practices. The joint called

- 419 dataset containing all 53,420 individuals processed by Hail framework<sup>73</sup> for further 1) genotype, 2)
- 420 variant, and 3) sample quality controls. First, we split the multi-allelic site into biallelic by split multi hts
- 421 function. Following this process, we removed low-quality genotypes and genotypes called by
- 422 unbalanced allele balance. We consider genotypes that meet the following criteria as missing: For
- 423 reference homozygotes: total depth (DP) < 10, or Genotype Quality (GQ) < 20. For heterozygotes: DP
- 424 < 10, Genotype Likelihood for reference homozygote (PL) < 20, (Reference depth + A1 depth)/DP < 0.8,
- 425 or (A1 depth)/DP < 0.2. For alternate homozygotes: DP < 10, PL < 20, or (A1 depth)/DP < 0.8.
- 426 Following genotype quality control, we conducted variant-level quality control. First, we filtered variants
- 427 in the low complexity region or outside of the target region
- 428 (broad custom exome v1.Homo sapiens assembly38.bed) with 50bp flanks. We excluded i)
- 429 monomorphic variants and, ii) variants with high missing rate (>10%). Using a quality-controlled variant
- 430 set, we conducted sample-level quality control. We collected sample QC metric by Hail's sample\_qc
- 431 function. We implemented five hard filters (percent chimeric reads, percent contamination, call rate,
- 432 mean depth, and mean genotyping quality, Supplemental Information Figure 8) and four soft filters
- 433 (number of singletons, Ts/Tv ratio, Het/Hom variant ratio, and Insertion/Deletion ratio, Supplemental
- 434 Information Figure 9). For soft filters, we obtained residuals of metrics regressing by the first ten genetic
- 435 PCs and excluded +/- 4SD outliers. Finally, using only unrelated quality-controlled samples, we
- 436 computed Hardy-Weinberg P-values by continental ancestry estimated from genotyping data. Hardy-
- 437 Weinberg P-values in chromosome X was computed only for Female participants. We excluded
- 438 variants with ancestry-wise Hardy-Weinberg P-values < 1 x 10<sup>-6</sup> or monomorphic variant. After quality
- 439 control steps, 7,895,027 variants in 22 autosomes and chromosome X were found in 50,625 individuals 440 remained.

#### 441 **Relatedness inference**

442 We utilized the pc relate<sup>74</sup> function from Hail to adjust for the presence of an admixed population within 443 the MGBB, using 91,615 pruned, common (MAF > 1%) variants that are located outside the major

- histocompatibility complex (chromosome 6 24,000,000 37,000,000 base pair). Among 53,306
- individuals, we identified 3,147 pairs with a kinship greater than 0.0884.

### **Derivation of genetic principal components**

- To obtain insights utilizing reference populations, first we combined array genotypes from unrelated
- MGBB participants with recently generated whole genome sequence datasets from ancestrally diverse
- 449 populations including 3,381 individuals from 1KG and  $HGDP^{28}$ . We intersected 495,213 autosomal,
- non-palindromic variants outside the high LD region with minor allele counts  $\geq 10$ . After merging two
- 451 datasets, we pruned variants by PLINK2 software<sup>71</sup> with –indep-pairwise option 1000 100 0.2 resulting
- in 257,754 variants. Using these genotypes, we derived the weight for each variant for PCs excluding
- related samples. Using derived weights, we calculated 30 PCs for all the individuals from MGBB, 1KG,
- and HGDP which were used in subsequent analysis.

## **Fixation index**

456 Pairwise Fixation indices ( $F_{ST}$ ) were computed among in MGBB-, 1KG- and HGDP- populations using

- 457 PLINK2 software. The phylogenetic tree was constructed neighbor-joining method<sup>75</sup> implemented by
- 458 ape R package<sup>76</sup>.

## **ADMIXTURE analysis**

Using PCs derived above, we conducted admixed component analysis using ADMIXTURE software 461 (version 1.3.0)<sup>29</sup>. We optimized the number of admix component K from 1 to 20 and found that K = 10 showed the least cross-validation error (Supplemental Information Figure 3).

## **Genetic ancestral clustering**

To derive fine-scale genetic clusters in the population, we conducted Graph-based clustering which is frequently used in single-cell RNA-seq clustering analysis implemented in Seurat software (version

466  $\pm$  4.1.0)<sup>25</sup>. Though Seurat is primarily tailored for single-cell RNA seq data analyses, we leveraged its

- robust clustering capabilities for genetic ancestry clustering. Using the first 30 PCs derived above, we
- constructed a nearest-neighbor graph and classified individuals into distinct clusters using the Louvain algorithm, a default clustering approach in Seurat with resolution parameter of 0.2. As Seurat identified
- the clusters in an unsupervised mode, we used individuals from the 1KG or HGDP as a "spike in"
- positive controls (true labels).

## **Effective population size estimation**

To estimate the effective population size using haplotype sharing information, we used IBDNe in

combination with the hap-ibd. First, we phased the genotypes of unrelated MGBB participants with

- 475 SHAPEIT software (version 4.2). Then, using hap-ibd software (version 1.0, 15Jun23.92f)<sup>77</sup>, we
- 476 calculated IBD sharing, and this output was fed into IBDNe software (version 23Apr20)<sup>78</sup> to determine
- 477 the effective population size for each ancestry. To compare the effective population size trajectories in
- 478 British population in UK and MGBB, we computed effective population size in down-sampled, unrelated
- 479 UKBB European-like population to the same sample size as MGBB British-like population (n=11,508),
- 480 using microarray-based genotypes.

#### 481 **Variant annotation**

- 482 We annotated WES data using the VEP software (version 107)<sup>79</sup>, supplemented with the Loftee<sup>30</sup> and
- 483 dbNFSP<sup>80</sup> plugins. The "—pick" option was enabled to prioritize the canonical transcript. Additionally,
- 484 in-silico predictions from dbNFSP (version 4.2) were employed to prioritize missense variants.

### 485 **Pathogenic variant annotation**

- 486 We downloaded ClinVar database<sup>45,46</sup> on Aug 16, 2022, and annotated all the variants identified by
- 487 exome sequence using snpEff software (version 5.0e)<sup>81</sup>. We identified 536,729 variants registered in
- 488 the ClinVar Database overall. To identify the carriers of pathogenic/likely pathogenic variants in the
- 489 ACMG SF v3.1 actionable genes<sup>43,44</sup>, we only used variants with review status
- 490 "reviewed by expert panel", "criteria provided, multiple submitters, no conflicts"

## 491 **Polygenic risk score**

- 492 Using the PRS-CS software<sup>82</sup>, we determined posterior weights for 1.2 million hapmap3 SNPs from a 493 previous CAD GWAS<sup>42</sup>, which did not include the MGBB/UKBB population. Given our study's 494 predominant European population, we utilized the European reference panel provided by the PRS-CS 495 authors. Our model training and derivation of posterior weights incorporated parameters phi ranging 496 from  $1 \times 10^{-1}$ ,  $1 \times 10^{-2}$ ,  $1 \times 10^{-3}$ ,  $1 \times 10^{-4}$ , and  $1 \times 10^{-5}$ . With these weights, we determined the CAD-
- 497 PRS for both UKBB and MGBB populations. From the UKBB results, we identified the optimal
- 498 parameter phi as  $1 \times 1 \times 10^{-3}$  and applied this PRS in the MGBB analysis.

## 499 **Disease Phenotyping**

- 500 We obtained patient data from the electronic health record system within the MGB network. We
- 501 specifically extracted ICD9 and ICD10 codes assigned to each patient. To enhance the interpretability
- 502 and powered analysis of the disease outcome, we employed the PheWAS R package (version 1.2)<sup>83</sup> to
- 503 map these codes to corresponding PheCodes<sup>24</sup>. The PheWAS package utilizes a comprehensive
- 504 catalog of PheCodes (https://phewascatalog.org/phecodes). This mapping process facilitated a more
- 505 standardized and consistent representation of the patient's conditions for subsequent analyses. To

- determine the prevalence or incidence of diseases, we considered the date of blood draw for
- genotyping as the reference date. By aligning with the corresponding date of PheCodes occurrences,
- we identified the prevalent or incident outcomes related to the date of enrollment in MGBB.

#### **Clinical risk, genetic risk, and social risk for CAD**

For the CAD analysis, we calculated the 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk

- 511 scores based on the PCE using the *PooledCohort* R package<sup>39,40,84</sup>. The PCE accounts for sex, race,
- age, total and HDL cholesterol, systolic blood pressure, antihypertensives prescription, current smoking,
- and prevalence of diabetes mellitus. For missing values, we performed multiple imputation by chained
- 514 equations using the *mice* R package<sup>85</sup>, using enrollment age, sex, and race as predictors. Among
- participants without prior CAD, the first post-enrollment CAD incidence was ascertained based on
- relevant ICD-9 and ICD10 codes from in-hospital records. We assessed the individual association of
- 10-year ASCVD risk, CAD-PRS, and SDI with incident CAD based on logistic regression.

#### **Exome-wide burden test**

- We conducted a rare variant aggregation burden test implemented in Regenie software (version
- $3.2.5$ <sup>86</sup>. We generated masks comprised of predicted loss of function (high confidence by Loftee
- 521 software<sup>30</sup>) and damaging missense variants predicted by  $>$  90% of 29 in-silico prediction programs
- 522 included in dbNFSP (version 4.2)<sup>80</sup> with MAF < 0.01.

#### **Genome-wide, phenome-wide association study**

- We conducted single variant PheWAS using imputed genotypes and 1,461 PheCodes. We applied 525 mixed model approach implemented in Regenie software (version 3.2.5)<sup>86</sup>. Null model was fit using pruned common variants derived from microarray-derived genotypes (MAF > 1%, pruned by PLINK2 527 software<sup>71</sup> with option –indep-pairwise 1000 100 0.9). The analyses were conducted ancestry wise. For sex specific endpoint, only male or female were included in the analysis. The genome-wide significant 529 threshold was set at  $P = 1.6 \times 10^{-11}$  dividing conventional genome-wide significant threshold 5  $\times$  10<sup>-8</sup> by 3,048 tested phenotypes across three ancestries. To define the associated loci, we added the flanking 531 region ( $\pm$  500,000 base-pairs) for all the variants with genome-wide significance (P < 1.6  $\times$  10<sup>-11</sup>) and
- merged all overlapping regions.

## **PheWAS Inflation statistics**

We estimated Lambda GC (observed chi-squared value divided by expected value) i) at top 1.0

percentile of the test statistics for rare variant burden PheWAS, and ii) using HapMap3 SNPs for

536 common variant PheWAS. For common variant PheWAS, LD score regression $^{87}$  was additionally performed to estimate intercept using ldscr R package (https://github.com/mglev1n/ldscr).

#### **Geocoding**

The participants' current address data was geocoded using the DeGAUSS framework<sup>88</sup>, a collection of geospatial tools designed for cleaning and formatting geographic data. This process converts the address information into standardized spatial data, specifically latitude and longitude coordinates. Our analysis focused on participants residing in Massachusetts. We excluded 1) Participants whose addresses were located outside of the state of Massachusetts, 2) Participants for whom the geocoding process failed. We successfully geocoded 48,369 individuals with genotype data.

#### **Area-based deprivation score index**

For individuals whose addresses were successfully geocoded, we proceeded with the following steps: 547 A) We assigned each individual's address to a corresponding U.S. Census tract. Census tracts are small, relatively stable geographic areas that are defined by the United States Census Bureau. They are designed to be relatively homogeneous units with respect to population characteristics, economic status, and living conditions. B) We then merged this Census tract-level data with SDI (2018 SDI, 551 downloaded from https://www.graham-center.org/maps-data-tools/social-deprivation-index.html)<sup>54</sup>. SDI is a composite measure of area level deprivation based on seven demographic characteristics collected in the American Community Survey (ACS) and used to quantify the socio-economic variation in health outcomes. The final SDI is a composite measure of seven demographic characteristics collected in the ACS: percent living in poverty, percent with less than 12 years of education, percent single-parent households, the percentage living in rented housing units, the percentage living in the overcrowded housing unit, percent of households without a car, and percentage non-employed adults under 65 years of age. This approach allows for a detailed, regional census tract-level analysis of the social conditions experienced by the study participants.

#### **Spatial enrichment analysis**

561 We utilized the Bernoulli model in SaTScan $^{89}$ . Under this model, individuals belonging to a specific genetic cluster were treated as "cases," while all other individuals were treated as "controls." This model compares the rates of cases in different areas to determine if the rate of cases inside the potential cluster area is significantly different from outside. To avoid detecting overly large and potentially less meaningful clusters, we limited our scan by setting the maximal diameter of the spatial cluster window. Specifically, we restricted this to a maximum radius of 4 kilometers.

**Data availability** 

22 September 2022 - 22 Septemb<br>2022 - 22 September 2022 - 22

- Genotyping and exome sequencing data for 13,500 participants from the MGBB are available in dbGAP
- (https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study\_id=phs002018.v1.p1).
- Additional MGBB data were accessed under institutional review board protocol for this current study
- and are not publicly available due to restrictions on the data. The summary statistics for phenome-wide
- common/rare variant association analysis and the allele frequencies of genetic clusters will be publically
- available upon the publication.

#### **Acknowledgements**

#### **Funding sources**

S.K. is supported by Japan Society for the Promotion of Science (202160643), Uehara Memorial Foundation, and National Institute of Health (NIH), National Heart Lung and Blood Institute (NHLBI, K99HL169733). K.P is supported by the MGH Executive Committee for Research Fund for Medical Discovery. S.J.C. is supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (HI19C1330). S.M.U. is supported by NIH National Human Genetics Research Institute (NHGRI, T32HG010464). R.C.G. is supported by NIH (HG009922, OD026553, HL143295, TR003201). B.M.N. is supported by R37MH107649. P.T.E. is supported by grants from the NIH (1R01HL092577, 1R01HL157635, 5R01HL139731), from the American Heart Association (18SFRN34230127, 961045), and from the European Union (MAESTRIA 965286). J.W.S. is supported by OT2OD026553, U01HG008685, MH118233. M.L. is supported by grants from the NIH (OT2OD002750, R01HL143295, U01HG008685, U01TR003201, and U24HG006834). E.K. is supported by grants from the NIH (OT2OD026553, U01HG008685, P30 AR070253, OT2HL161841). A.R.M. and Y.W. are supported by NIH, NHGRI (K99/R00MH117229 to A.R.M.) and by European Union's Horizon 2020 research and innovation program under grant agreement 101016775. A.R.M. is also supported by U01HG011719. P.N. is supported by grants from the NHLBI (R01HL127564), and NHGRI (U01HG011719).

## **Declaration of interests**

K.P. reports research grants, paid to her institution, from Allelica, Apple, Amgen, AstraZeneca, Boston Scientific, Genentech / Roche, and Ionis. R.C.G. has received compensation for advising the following companies: Allelica, Atria, Fabric, Genome Web, Genomic Life and Juniper Genomics; and is co-founder of Genome Medical and Nurture Genomics. M.J.D is a founder of Maze Therapeutics and is a member of the scientific advisory board for Neumora Therapeutics, Inc. (formerly known as RBNC Therapeutics). B.M.N. is a member of the scientific advisory board at Deep Genomics and Neumora Therapeutics, Inc. J.W.S. is a member of the Scientific Advisory Board of Sensorium Therapeutics (with equity), and has received grant support from Biogen, Inc. P.T.E. receives sponsored research support from Bayer AG, IBM Research, Bristol Myers Squibb, Pfizer and Novo Nordisk; he has also served on advisory boards or consulted for MyoKardia and Bayer AG. J.W.S. is PI of a collaborative study of the genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no payments. P.N. reports research grants from Allelica, Apple, Amgen, Boston Scientific, Genentech / Roche, and Novartis, personal fees from Allelica, Apple,

- AstraZeneca, Blackstone Life Sciences, Eli Lilly & Co, Foresite Labs, Genentech / Roche, GV,
- HeartFlow, Magnet Biomedicine, and Novartis, scientific advisory board membership of Esperion
- Therapeutics, Preciseli, and TenSixteen Bio, scientific co-founder of TenSixteen Bio, equity in MyOme,
- Preciseli, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the
- present work.

#### **Author contributions**

- R.C.G., M.J.D., B.M.N., P.T.E., E.W.K., A.R.M., and P.N. conceptualized this project. S.K., K.P., S.J.C.,
- and E.W.K. curated phenotype data. S.K., and M.S.L. curated genotype data. S.K., M.U., and S.M.U.
- analyzed data. S.K., Y.W., P.T.E., E.W.K., A.R.M., and P.N. interpreted data. S.K., A.R.M., and P.N.
- prepared the initial draft. Y.W., K.P., M.U., S.J.C., W.E.H., R.C.G., M.J.D., B.M.N., P.T.E., J.W.S.,
- E.W.K., A.R.M., and P.N. provided critical review and edits for the manuscript. S.H., W.E.H., R.C.G.,
- M.J.D., B.M.N., P.T.E., E.W.K., A.R.M., and P.N. supervised the project. S.H., W.E.H., P.T.E., J.W.S.,
- M.S.L., and E.W.K. managed the project administration. P.T.E., J.W.S., M.S.L., E.W.K., and P.N.
- obtained funding for the project.

## **Figure Legends**

### **Figure 1 | The cohort characteristics of MGBB**

**a,** The columns represent the cumulative number of individuals who have consented to the MGBB.

Colors indicate the vital status of participants as of May 2023. **b,** Gender/Age at Consent Distribution:

- The columns represent the distribution of the participants based on gender and age at the time of
- consent. The individuals older than 100 years at the time of consent are not included in the displayed
- numbers. **c,** Encounter patterns in the MGB Network. The number of encounters that participants have
- had within the MGB network. Please note that these encounters include sites where recruitment did not
- take place. **d,** Distribution of PheCodes based outcomes. The columns indicate the number of
- outcomes in PheCode-category. Colors distinguish between incident and prevalent cases. MGH,
- Massachusetts General Hospital; BWH, Brigham's and Women's Hospital, MEEI Mass Eye and Ear
- Institute; FH Faulkner Hospital; NWH, Newton-Wellesley Hospital; DFCI, Dana-Farber Cancer Institute.

## **Figure 2 | Fine-scale genetic clusters within MGBB**

**a,** and **b,** UMAP representation of genetic clusters in MGBB. Each dot represents a participant, with

- colors indicating distinct genetic clusters identified through graph-based clustering from genetic
- principal components (Methods). The numbers indicate cluster identification. The color legend and
- detailed cluster information will be found in Supplemental Table 2 and Figure S2. **c,** Population
- differentiation in MGBB revealed by ADMIXTURE analysis. The heatmap displays the proportions of
- 639 ADMIXTURE components  $(K = 10)$  within each genetic cluster. The columns at the top of the heatmap
- represent the number of MGBB participants in each cluster. UMAP, Uniform Manifold Approximation
- and Projection; MGBB, Mass General Brigham Biobank

## **Figure 3 | Geospatial distribution, socioeconomic status, and disease risks in MGBB**

- **a,** Geographical enrichment of genetic ancestries in the greater Boston area. The circle indicates area of significant enrichment of corresponding genetic ancestries. **b,** We tested the association between the socioeconomic deprivation index (SDI) and 1,564 PheCodes based outcomes (Prevalence + Incidence) in 47,070 MGBB participants. The model was adjusted for age, sex, and the first ten genetic principal 647 components. An association was considered statistically significant if *P*-value was less  $3.2 \times 10^{-5}$
- (0.05/1,564). The color of bars indicated the direction of the effect of SDI (higher SDI suggests higher
- deprivation). **c,** The disease frequency (prevalence + incidence) by deprivation status and genetic
- ancestry. The color of bars indicated deprivation status (higher or lower than the median SDI).
- Complication of Birth, Other and unspecified complications of birth; puerperium affecting management
- of mother (PheCode 654).

## **Figure 4 | Rare variant identification in the MGBB**

**a,** Distribution of the number of protein-truncating variants across genetic ancestries. Each dot represents a participant. The horizontal axis represents the genetic ancestries in the MGBB, while the

- vertical axis represents the number of protein-truncating alleles in each participant. **b,** Carrier counts of
- pathogenic/likely pathogenic variants in ACMG actionable genes. The colors of the bars indicate the
- mode of inheritance of the genes. **c,** Carrier frequency of individuals with pathogenic variants in ACMG
- actionable genes, categorized by ancestry. The colors of the bars correspond to the continental
- ancestries. The dotted line represents the average frequency in the MGBB. **d,** Summary of phenome-
- wide gene burden testing in the MGBB. We conducted exome-wide phenome wide association analysis

across 1,454 PheCodes based outcomes in 14,912 genes. The columns indicate the number of 663 significant associations (P <  $1.8 \times 10^{-9} = 5 \times 10^{-2}/28,035,307$  phenotype-transcript pairs) for designated genes. The color of each column corresponds to the associated PheCode-category. MGBB, Mass General Brigham Biobank; ACMG, American College of Medical Genetics and Genomics; pLOF, predicted loss of function; AFR, African; AMR, Admixed-American; EAS, East Asian; EUR, European; SAS, South Asian.

#### **Figure 5 | Common variant association study in the MGBB**

**a,** Number of associations in the common variant phenome-wide association analysis in MGBB. 670 We conducted associations between common genetic variants (Minor allele counts ≥ 40) and 671 1,461 PheCodes (Case counts ≥ 60), categorized by continental ancestries (AFR, n = 2,846; 671 1,461 PheCodes (Case counts ≥ 60), categorized by continental ancestries (AFR, n = 2,846;<br>672 AMR, n = 3,756; EUR, n = 44,163). The columns represent the number of significant AMR,  $n = 3,756$ ; EUR,  $n = 44,163$ ). The columns represent the number of significant 673 associations ( $P < 1.6 \times 10^{-11}$ ) on each chromosome. The color indicates the ancestry in which the association was observed. We annotated chromosomes with more than 10 associations, indicating the representative locus in the chromosome. **b,** Manhattan plot of GWAS for Rhesus 676 isoimmunization during pregnancy in women ( $n = 23,959$ ). The horizontal axis displays the genomic coordinates from chromosome 1 to chromosome X. The vertical axis represents the 678 strength of association in negative log<sub>10</sub> P-value. The significantly associated variants in the *RHD* locus is highlighted. **c,** Odds ratio for Rhesus isoimmunization during pregnancy by rs72660908 genotypes. The dots and error bars represent the estimated odds ratios and 95% confidence intervals compared to the reference homozygotes ([C/C]). **d,** *RHD* read counts from Whole Blood RNA sequence data obtained from the GTEx dataset. The horizontal axis displays the number of reads aligned to the *RHD* gene, categorized by rs72660908 genotypes. **e,** Frequencies of rs72660908 homozygotes across genetic clusters in MGBB. The horizontal axis corresponds to the genetic ancestries in MGBB, while the vertical axis represents the ancestral frequency of rs72660908 homozygotes ([G/G]). The colors of the columns correspond to continental ancestries. MGBB, Mass General Brigham Biobank; ACMG, American College of Medical Genetics and Genomics; pLOF, predicted loss of function; AFR, African; AMR, Admixed-American; EAS, East Asian; EUR, European; SAS, South Asian; GWAS, Genome-Wide Association Study; GTEx, Genotype-Tissue Expression.

## **Supplemental Figure Legends**

### **Figure S1 | Projection of the fine genetic clusters in the continental ancestry space**

**a,** The distribution of the continental ancestries in the UMAP space. Each point on the plot represents an individual participant of MGBB. To infer the continental ancestry of each participant, we utilized the K-nearest neighbor algorithm trained on the 1000 Genomes Project dataset. The colors assigned to the points represent the inferred continental ancestries. The horizontal axis corresponds to the first axis of the UMAP projection, and the vertical axis represents the second axis. This two-dimensional representation allows us to visualize the clustering and distribution patterns of different continental ancestries within the MGBB population. **b,** The distribution of the fine-scale genetic clusters in the MGBB on conventional PC space. Each point on the plot represents an individual in MGBB. The colors assigned to the points represent genetic clusters inferred by the network-based clustering method (Methods). The horizontal axis corresponds to the first genetic PC, and the vertical axis represents the second genetic PC. UMAP, Uniform Manifold Approximation and Projection; MGBB, Mass General

Brigham Biobank; PC, principal component.

## **Figure S2 | Enrichment of the reference groups in the genetic clusters inferred in MGBB**

The horizontal axis shows reference populations from 1000 Genomes Project and Human Genome Diversity Project. The vertical axis shows genetic clusters inferred from MGBB. In the left panel, the heights of bars show the number of MGBB participants included in the genetic clusters. In the right panel, the size and transparency of rectangle shows intersection size between reference population and genetic clusters. The number of individuals in the clusters and the color legend are found in

- Supplemental Table 2. Abbreviations for reference populations will be find in Supplemental Table 7.
- MGBB, Mass General Brigham Biobank.

## **Figure S3 | ADMIXTURE analysis for reference population (1KG + HGDP) and genetic clusters**

**a,** Phylogenetic tree generated using *F*st Values. The phylogenic tree was constructed using the Neighbor-Joining method with pairwise *F*st values serving as a measure of genetic distance between populations. A higher *F*st value indicates a greater genetic differentiation between populations. The numeric numbers indicate genetic cluster in MGBB. Ancestry names indicated reference populations in 1KG or HGDP. The number indicate genetic clusters in MGBB. **b,** In each panel, a stacked column of color segments represents an individual participant. The color of each segment corresponds to one of the K = 10 ancestral components, as determined by ADMIXTURE software. The length of each colored segment within a participant's column indicates the estimated proportion of their genome attributed to 722 that specific ancestral population. The choice of  $K = 10$  was informed by cross-validation results, with the aim of minimizing prediction error (Supplemental Information Figure 3). The abbreviations and detailed descriptions for the ancestral populations corresponding to each color are provided in Supplemental Table 7. 1KG, 1000 Genomes Project; HGDP, Human Genome Diversity Project; MGBB,

Mass General Brigham Biobank.

## **Figure S4 | Phenome wide association analysis for cluster 4**

Each dot represents the association results based on PheCodes. We examined the relationship

- between membership in genetic cluster 4 of the MGBB biobank and PheCodes outcomes. This
- association was assessed using a logistic regression model, adjusted for age and sex. MGBB, Mass
- General Brigham Biobank.

## **Figure S5 | Shared founder mutations across genetic clusters 4, 11, and 14**

- The left panels are showing the distribution of genetic cluster 4, 11, and 14 in the UMAP space. The
- right panel shows the distribution of Ashkenazi founder mutations described in the previous literatures.
- The horizontal axes show the genetic clusters identified in MGBB, and the vertical axes show the allele
- frequencies determined by whole exome sequencing of MGBB by the genetic clusters. UMAP, Uniform
- Manifold Approximation and Projection; MGBB, Mass General Brigham Biobank.

## **Figure S6 | Effective population sizes in the genetic clusters in MGBB**

- The horizontal axes show generations ago. The vertical axes show the estimated population size.
- Numbers on the top of panels show the cluster identification. The black lines show the estimates and 741 gray lines show 95% confidence interval.

## **Figure S7 | Geographical, socioeconomical, distributions of genetic clusters**

- Distributions of socioeconomic (**a**), clinical (**b**), and genetic risks (**c**). Each dot indicates MGBB
- participants. The horizontal axes show genetic cluster. SDI, social deprivation index; PCE, pooled
- cohort equation, CAD PRS, polygenic risk score for coronary artery disease.

## **Figure S8 | Social deprivation in Massachusetts and Greater Boston Area**

- The color of each grid represents the median Social Deprivation Index (SDI) of the participants from
- MGBB. A darker shade denotes a higher level of socioeconomic deprivation. Grids with fewer than five
- participants have been excluded.

## **Figure S9 | Different annotation rate for the functional variants in the pathogenic genes**

- **a,** The bar heights depict the proportion of pLOF variants in ACMG genes within specific genetic
- clusters identified in MGBB with pathogenic/likely pathogenic annotations as determined by multiple
- expert reviews in ClinVar. **b,** The odds ratio indicates the likelihood of pLOF variants in ACMG genes
- having pathogenic/likely pathogenic annotations based on multiple expert reviews. The results are
- presented in the continental ancestries and in reference to the European population. Error bars indicate
- 95% confidence intervals. OR, Odds Ratio; AFR, African; AMR, Admixed American; EAS, East Asian;
- EUR, European; SAS, South Asian. ACMG, American College of Medical Genetics and Genomics;
- MGBB, Mass General Brigham Biobank; pLOF predicted loss of function.

## **Figure S10 | Penetrant association of rs334 for sickle cell anemia**

- **a,** The prevalence of Sickle cell anemia by rs334 genotypes. **b,** The RBC measurements in the MGB
- participants by combined genotype of rs33930165 and rs334. The box plot depicts the first and third
- quartiles, with the line inside the box indicating the median value. RBC, Red Blood Cell count.

#### 763 **References**

- 764 1. Townsend, P., Phillimore, P., and Beattie, A. (1988). Health and Deprivation: Inequality and the North (Routledge).
- 766 2. Li, X., Memarian, E., Sundquist, J., Zöller, B., and Sundquist, K. (2014). Neighbourhood Deprivation,<br>767 **Indivialise of Francial and Socio-Demographic Factors and Diagnosed Childhood Obesity: A** 767 Individual-Level Familial and Socio-Demographic Factors and Diagnosed Childhood Obesity: A<br>768 **Industry of Study And Andrew Study from Sweden**. Obesity Facts 7, 253-263, 10.1159/000365955. 768 Nationwide Multilevel Study from Sweden. Obesity Facts *7*, 253-263. 10.1159/000365955.
- 769 3. Bann, D., Johnson, W., Li, L., Kuh, D., and Hardy, R. (2018). Socioeconomic inequalities in<br>770 childhood and adolescent body-mass index, weight, and height from 1953 to 2015: an analy 770 childhood and adolescent body-mass index, weight, and height from 1953 to 2015: an analysis of 771 four longitudinal, observational, British birth cohort studies. Lancet Public Health *3*, e194-e203. 772 10.1016/S2468-2667(18)30045-8.
- 773 4. Fan, J.X., Wen, M., and Li, K. (2020). Associations between obesity and neighborhood 774 socioeconomic status: Variations by gender and family income status. SSM Popul Health *10*, 775 100529. 10.1016/j.ssmph.2019.100529.
- 776 5. Akiyama, M., Okada, Y., Kanai, M., Takahashi, A., Momozawa, Y., Ikeda, M., Iwata, N., Ikegawa, S., Anai, M., Integawa, S., Anai, A., Integawa, S., Anai, A., Integawa, S., Anai, A., Integawa, S., Anai, A., Integawa, 777 Hirata, M., Matsuda, K., et al. (2017). Genome-wide association study identifies 112 new loci for 778 body mass index in the Japanese population. Nat Genet 49, 1458-1467. 10.1038/ng.3951. 778 body mass index in the Japanese population. Nat Genet *49*, 1458-1467. 10.1038/ng.3951.
- 779 6. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., 780 780 Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with deep phenotyping and<br>781 genomic data. Nature 562, 203-209. 10.1038/s41586-018-0579-z. 781 genomic data. Nature *562*, 203-209. 10.1038/s41586-018-0579-z.
- 782 7. Zhou, W., Kanai, M., Wu, K.H., Rasheed, H., Tsuo, K., Hirbo, J.B., Wang, Y., Bhattacharya, A., Zhao, 783 H., Namba, S., et al. (2022). Global Biobank Meta-analysis Initiative: Powering genetic discovery 784 across human disease. Cell Genom *2*, 100192. 10.1016/j.xgen.2022.100192.
- 785 8. Kurki, M.I., Karjalainen, J., Palta, P., Sipila, T.P., Kristiansson, K., Donner, K.M., Reeve, M.P., 786 Laivuori, H., Aavikko, M., Kaunisto, M.A., et al. (2023). FinnGen provides genetic insights from a 787 well-phenotyped isolated population. Nature *613*, 508-518. 10.1038/s41586-022-05473-8.
- 788 9. Belbin, G.M., Cullina, S., Wenric, S., Soper, E.R., Glicksberg, B.S., Torre, D., Moscati, A., Wojcik, 789 (G.L., Shemirani, R., Beckmann, N.D., et al. (2021). Toward a fine-scale population health monitority 789 G.L., Shemirani, R., Beckmann, N.D., et al. (2021). Toward a fine-scale population health monitoring<br>790 system. Cell 184, 2068-2083 e2011. 10.1016/i.cell.2021.03.034. 790 system. Cell *184*, 2068-2083 e2011. 10.1016/j.cell.2021.03.034.
- 791 10. Verma, A., Damrauer, S.M., Naseer, N., Weaver, J., Kripke, C.M., Guare, L., Sirugo, G., Kember, 792 R.L., Drivas, T.G., Dudek, S.M., et al. (2022). The Penn Medicine BioBank: Towards a Genomics-792 R.L., Drivas, T.G., Dudek, S.M., et al. (2022). The Penn Medicine BioBank: Towards a Genomics-793 Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population. J<br>794 Pers Med 12. 10.3390/ipm12121974. 794 Pers Med *12*. 10.3390/jpm12121974.
- 795 11. Brumpton, B.M., Graham, S., Surakka, I., Skogholt, A.H., Loset, M., Fritsche, L.G., Wolford, B., Zhou,<br>796 W., Nielsen, J.B., Holmen, O.L., et al. (2022). The HUNT study: A population-based cohort for 796 W., Nielsen, J.B., Holmen, O.L., et al. (2022). The HUNT study: A population-based cohort for<br>797 genetic research. Cell Genom 2, 100193. 10.1016/j.xgen.2022.100193. 797 genetic research. Cell Genom *2*, 100193. 10.1016/j.xgen.2022.100193.
- 798 12. Johnson, R., Ding, Y., Bhattacharya, A., Knyazev, S., Chiu, A., Lajonchere, C., Geschwind, D.H., 799 and Pasaniuc. B. (2023). The UCLA ATLAS Community Health Initiative: Promoting precision health 799 and Pasaniuc, B. (2023). The UCLA ATLAS Community Health Initiative: Promoting precision health 790<br>800 research in a diverse biobank. Cell Genom 3, 100243. 10.1016/j.xgen.2022.100243. 800 research in a diverse biobank. Cell Genom *3*, 100243. 10.1016/j.xgen.2022.100243.
- 801 13. Zawistowski, M., Fritsche, L.G., Pandit, A., Vanderwerff, B., Patil, S., Schmidt, E.M., VandeHaar, P.,<br>802 Willer, C.J., Brummett, C.M., Kheterpal, S., et al. (2023). The Michigan Genomics Initiative: A 802 Willer, C.J., Brummett, C.M., Kheterpal, S., et al. (2023). The Michigan Genomics Initiative: A<br>803 biobank linking genotypes and electronic clinical records in Michigan Medicine patients. Cell G 803 biobank linking genotypes and electronic clinical records in Michigan Medicine patients. Cell Genom 804 *3*, 100257. 10.1016/j.xgen.2023.100257.
- 805 14. Soria, L.F., Ludwig, E.H., Clarke, H.R., Vega, G.L., Grundy, S.M., and McCarthy, B.J. (1989). 806 Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100.<br>807 Proceedings of the National Academy of Sciences 86, 587-591. 10.1073/pnas.86.2.587. 807 Proceedings of the National Academy of Sciences *86*, 587-591. 10.1073/pnas.86.2.587.

- 808 15. Shen, H., Damcott, C.M., Rampersaud, E., Pollin, T.I., Horenstein, R.B., McArdle, P.F., Peyser, P.A.,<br>809 Seleak, L.F., Post, W.S., Chang, Y.-P.C., et al. (2010). Familial Defective Apolipoprotein B-100 and 809 Bielak, L.F., Post, W.S., Chang, Y.-P.C., et al. (2010). Familial Defective Apolipoprotein B-100 and<br>810 Increased Low-Density Lipoprotein Cholesterol and Coronary Artery Calcification in the Old Order 810 Increased Low-Density Lipoprotein Cholesterol and Coronary Artery Calcification in the Old Order 811 Amish. Archives of Internal Medicine *170*. 10.1001/archinternmed.2010.384.
- 812 16. Cohen, J.C., Boerwinkle, E., Mosley, T.H., and Hobbs, H.H. (2006). Sequence Variations in*PCSK9,* 813 Low LDL, and Protection against Coronary Heart Disease. New England Journal of Medicine *354*, 814 1264-1272. 10.1056/nejmoa054013.
- 815 17. Cohen, J., Pertsemlidis, A., Kotowski, I.K., Graham, R., Garcia, C.K., and Hobbs, H.H. (2005). Low 816 UDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in 816 LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in 817 CSK9. Nature Genetics 37, 161-165. 10.1038/ng1509. 817 PCSK9. Nature Genetics *37*, 161-165. 10.1038/ng1509.
- 818 18. Luzzatto, L., Ally, M., and Notaro, R. (2020). Glucose-6-phosphate dehydrogenase deficiency. Blood<br>819 136, 1225-1240. 10.1182/blood.2019000944. 819 *136*, 1225-1240. 10.1182/blood.2019000944.
- 820 19. Manrai, A.K., Funke, B.H., Rehm, H.L., Olesen, M.S., Maron, B.A., Szolovits, P., Margulies, D.M., 821 Loscalzo, J., and Kohane, I.S. (2016). Genetic Misdiagnoses and the Potential for Health Dispariti 821 Loscalzo, J., and Kohane, I.S. (2016). Genetic Misdiagnoses and the Potential for Health Disparities.<br>822 New England Journal of Medicine 375, 655-665. 10.1056/neimsa1507092. 822 New England Journal of Medicine *375*, 655-665. 10.1056/nejmsa1507092.
- 823 20. Aragam, K.G., Dobbyn, A., Judy, R., Chaffin, M., Chaudhary, K., Hindy, G., Cagan, A., Finneran, P., 824 Weng, L.C., Loos, R.J.F., et al. (2020). Limitations of Contemporary Guidelines for Managing<br>825 Patients at High Genetic Risk of Coronary Artery Disease. J Am Coll Cardiol 75, 2769-2780. 825 Patients at High Genetic Risk of Coronary Artery Disease. J Am Coll Cardiol *75*, 2769-2780. 826 10.1016/j.jacc.2020.04.027.
- 827 21. Baharian, S., Barakatt, M., Gignoux, C.R., Shringarpure, S., Errington, J., Blot, W.J., Bustamante, 828 C.D., Kenny, E.E., Williams, S.M., Aldrich, M.C., and Gravel, S. (2016). The Great Migration and 828 C.D., Kenny, E.E., Williams, S.M., Aldrich, M.C., and Gravel, S. (2016). The Great Migration and 829 African-American Genomic Diversity. PLOS Genetics *12*, e1006059. 10.1371/journal.pgen.1006059.
- 830 22. Han, E., Carbonetto, P., Curtis, R.E., Wang, Y., Granka, J.M., Byrnes, J., Noto, K., Kermany, A.R., 831 Wyres, N.M., Barber, M.J., et al. (2017). Clustering of 770,000 genomes reveals post-colonial 831 Myres, N.M., Barber, M.J., et al. (2017). Clustering of 770,000 genomes reveals post-colonial<br>832 population structure of North America. Nat Commun 8, 14238. 10.1038/ncomms14238. 832 population structure of North America. Nat Commun *8*, 14238. 10.1038/ncomms14238.
- 833 23. Dai, C.L., Vazifeh, M.M., Yeang, C.-H., Tachet, R., Wells, R.S., Vilar, M.G., Daly, M.J., Ratti, C., and<br>834 Martin, A.R. (2020). Population Histories of the United States Revealed through Fine-Scale 834 Martin, A.R. (2020). Population Histories of the United States Revealed through Fine-Scale<br>835 Migration and Haplotype Analysis. The American Journal of Human Genetics 106, 371-388. 835 Migration and Haplotype Analysis. The American Journal of Human Genetics *106*, 371-388. 836 10.1016/j.ajhg.2020.02.002.
- 837 24. Denny, J.C., Bastarache, L., Ritchie, M.D., Carroll, R.J., Zink, R., Mosley, J.D., Field, J.R., Pulley,<br>838 J.M., Ramirez, A.H., Bowton, E., et al. (2013). Systematic comparison of phenome-wide association 838 J.M., Ramirez, A.H., Bowton, E., et al. (2013). Systematic comparison of phenome-wide association<br>839 study of electronic medical record data and genome-wide association study data. Nat Biotechnol 31, 839 study of electronic medical record data and genome-wide association study data. Nat Biotechnol *31*, 840 1102-1110. 10.1038/nbt.2749.
- 841 25. Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J., Wilk, A.J.,<br>842 **Darby, C., Zager, M., et al. (2021).** Integrated analysis of multimodal single-cell data. Cell 184, 3573-842 Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-cell data. Cell *184*, 3573- 843 3587 e3529. 10.1016/j.cell.2021.04.048.
- 844 26. Bergstrom, A., McCarthy, S.A., Hui, R., Almarri, M.A., Ayub, Q., Danecek, P., Chen, Y., Felkel, S., 845 [1999]<br>845 Hallast, P., Kamm, J., et al. (2020). Insights into human genetic variation and population history 845 Hallast, P., Kamm, J., et al. (2020). Insights into human genetic variation and population history from 846 929 diverse genomes. Science *367*. 10.1126/science.aay5012.
- 847 27. Auton, A., Abecasis, G.R., Altshuler, D.M., Durbin, R.M., Abecasis, G.R., Bentley, D.R., Chakravarti, 848 (2015). A global reference for human genetic 848 A., Clark, A.G., Donnelly, P., Eichler, E.E., et al. (2015). A global reference for human genetic 849 849 variation. Nature *526*, 68-74. 10.1038/nature15393.
- 850 28. Koenig, Z., Yohannes, M.T., Nkambule, L.L., Goodrich, J.K., Kim, H.A., Zhao, X., Wilson, M.W., Tiao, 851 (3., Hao, S.P., Sahakian, N., et al. (2023). A harmonized public resource of deeply sequenced 851 G., Hao, S.P., Sahakian, N., et al. (2023). A harmonized public resource of deeply sequenced<br>852 diverse human genomes. Cold Spring Harbor Laboratory. diverse human genomes. Cold Spring Harbor Laboratory.

- 853 29. Alexander, D.H., Novembre, J., and Lange, K. (2009). Fast model-based estimation of ancestry in 854 (854).<br>854 The unrelated individuals. Genome Res 19, 1655-1664, 10.1101/gr.094052.109. 854 unrelated individuals. Genome Res *19*, 1655-1664. 10.1101/gr.094052.109.
- 855 30. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alfoldi, J., Wang, Q., Collins, R.L., 856 Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint spectrum<br>857 quantified from variation in 141.456 humans. Nature 581, 434-443. 10.1038/s41586-020-2308 857 quantified from variation in 141,456 humans. Nature *581*, 434-443. 10.1038/s41586-020-2308-7.
- 858 31. Laken, S.J., Petersen, G.M., Gruber, S.B., Oddoux, C., Ostrer, H., Giardiello, F.M., Hamilton, S.R., 859 femmel, H., Markowitz, A., Klimstra, D., et al. (1997). Familial colorectal cancer in Ashkenazim due 859 Hampel, H., Markowitz, A., Klimstra, D., et al. (1997). Familial colorectal cancer in Ashkenazim due 860 to a hypermutable tract in APC. Nature Genetics *17*, 79-83. 10.1038/ng0997-79.
- 861 32. Levy-Lahad, E., Catane, R., Eisenberg, S., Kaufman, B., Hornreich, G., Lishinsky, E., Shohat, M., 862 weber. B.L., Beller. U., Lahad. A., and Halle. D. (1997). Founder BRCA1 and BRCA2 mutations in Weber, B.L., Beller, U., Lahad, A., and Halle, D. (1997). Founder BRCA1 and BRCA2 mutations in 863 Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-<br>864 ovarian cancer families. Am J Hum Genet 60, 1059-1067. 864 ovarian cancer families. Am J Hum Genet *60*, 1059-1067.
- 865 33. Salmela, E., Lappalainen, T., Fransson, I., Andersen, P.M., Dahlman-Wright, K., Fiebig, A., Sistonen, 866 F., Savontaus, M.L., Schreiber, S., Kere, J., and Lahermo, P. (2008). Genome-wide analysis of 867 867 single nucleotide polymorphisms uncovers population structure in Northern Europe. PLoS One *3*, 868 e3519. 10.1371/journal.pone.0003519.
- 869 34. Huyghe, J.R., Fransen, E., Hannula, S., Van Laer, L., Van Eyken, E., Maki-Torkko, E., Aikio, P., 870<br>870 Sorri, M., Huentelman, M.J., and Van Camp, G. (2011). A genome-wide analysis of population 870 Sorri, M., Huentelman, M.J., and Van Camp, G. (2011). A genome-wide analysis of population<br>871 structure in the Finnish Saami with implications for genetic association studies. Eur J Hum Gen 871 structure in the Finnish Saami with implications for genetic association studies. Eur J Hum Genet *19*, 872 347-352. 10.1038/ejhg.2010.179.
- 873 35. Lazaridis, I., Patterson, N., Mittnik, A., Renaud, G., Mallick, S., Kirsanow, K., Sudmant, P.H., 874 Schraiber, J.G., Castellano, S., Lipson, M., et al. (2014). Ancient human genomes suggest three<br>875 https://www.faster.org/states.org/states.org/2014). Ancient human genomes suggest three 875 ancestral populations for present-day Europeans. Nature *513*, 409-413. 10.1038/nature13673.
- 876 36. Haak, W., Lazaridis, I., Patterson, N., Rohland, N., Mallick, S., Llamas, B., Brandt, G., Nordenfelt, S.,<br>877 Harney, E., Stewardson, K., et al. (2015). Massive migration from the steppe was a source for Indo-877 Harney, E., Stewardson, K., et al. (2015). Massive migration from the steppe was a source for Indo-<br>878 European languages in Europe. Nature 522, 207-211. 10.1038/nature14317. 878 European languages in Europe. Nature *522*, 207-211. 10.1038/nature14317.
- 879 37. Carmi, S., Hui, K.Y., Kochav, E., Liu, X., Xue, J., Grady, F., Guha, S., Upadhyay, K., Ben-Avraham, 880 880 D., Mukherjee, S., et al. (2014). Sequencing an Ashkenazi reference panel supports population-881 targeted personal genomics and illuminates Jewish and European origins. Nature Communications *5*, 882 4835. 10.1038/ncomms5835.
- 883 38. Browning, S.R., and Browning, B.L. (2007). Rapid and accurate haplotype phasing and missing-data<br>884 inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum 884 inference for whole-genome association studies by use of localized haplotype clustering. Am J Hum<br>885 Genet 81, 1084-1097. 10.1086/521987. 885 Genet *81*, 1084-1097. 10.1086/521987.
- 886 39. Browning, S.R., Browning, B.L., Daviglus, M.L., Durazo-Arvizu, R.A., Schneiderman, N., Kaplan, 887 K.C., and Laurie, C.C. (2018). Ancestry-specific recent effective population size in the Americas. 887 R.C., and Laurie, C.C. (2018). Ancestry-specific recent effective population size in the Americas.<br>888 PLoS Genet 14, e1007385. 10.1371/journal.pgen.1007385. 888 PLoS Genet *14*, e1007385. 10.1371/journal.pgen.1007385.
- 889 40. Goff, D.C., Lloyd-Jones, D.M., Bennett, G., Coady, S., D'Agostino, R.B., Gibbons, R., Greenland, P., 890 890 Lackland, D.T., Levy, D., O'Donnell, C.J., et al. (2014). 2013 ACC/AHA Guideline on the<br>891 Sessessment of Cardiovascular Risk: A Report of the American College of Cardiology/Am Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American 892 Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology<br>893 63, 2935-2959. https://doi.org/10.1016/j.jacc.2013.11.005. 893 *63*, 2935-2959. https://doi.org/10.1016/j.jacc.2013.11.005.
- 894 41. Goff, D.C., Lloyd-Jones, D.M., Bennett, G., Coady, S., D'Agostino, R.B., Gibbons, R., Greenland, P., 895 Lackland, D.T., Levy, D., O'Donnell, C.J., et al. (2014). 2013 ACC/AHA Guideline on the 896 Assessment of Cardiovascular Risk. Circulation *129*, S49-S73. 897 10.1161/01.cir.0000437741.48606.98.
- 898 42. A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery<br>899 disease. (2015). Nature Genetics 47, 1121-1130. 10.1038/ng.3396. 899 disease. (2015). Nature Genetics *47*, 1121-1130. 10.1038/ng.3396.

- 900 43. Miller, D.T., Lee, K., Abul-Husn, N.S., Amendola, L.M., Brothers, K., Chung, W.K., Gollob, M.H.,<br>901 Gordon. A.S., Harrison. S.M., Hershberger, R.E., et al. (2022). ACMG SF v3.1 list for reporting o 901 Gordon, A.S., Harrison, S.M., Hershberger, R.E., et al. (2022). ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American 903 College of Medical Genetics and Genomics (ACMG). Genetics in Medicine *24*, 1407-1414. 904 10.1016/j.gim.2022.04.006.
- 905 44. Miller, D.T., Lee, K., Chung, W.K., Gordon, A.S., Herman, G.E., Klein, T.E., Stewart, D.R., Amendola,<br>906 L.M., Adelman, K., Bale, S.J., et al. (2021). ACMG SF v3.0 list for reporting of secondary findings in 906 L.M., Adelman, K., Bale, S.J., et al. (2021). ACMG SF v3.0 list for reporting of secondary findings in<br>907 clinical exome and genome sequencing: a policy statement of the American College of Medical 907 clinical exome and genome sequencing: a policy statement of the American College of Medical<br>908 Genetics and Genomics (ACMG). Genet Med 23, 1381-1390. 10.1038/s41436-021-01172-3. 908 Genetics and Genomics (ACMG). Genet Med *23*, 1381-1390. 10.1038/s41436-021-01172-3.
- 909 45. Landrum, M.J., Lee, J.M., Benson, M., Brown, G.R., Chao, C., Chitipiralla, S., Gu, B., Hart, J., 910<br>910 Hoffman. D., Jang. W., et al. (2018). ClinVar: improving access to variant interpretations and 910 Hoffman, D., Jang, W., et al. (2018). ClinVar: improving access to variant interpretations and<br>911 supporting evidence. Nucleic Acids Res 46, D1062-D1067. 10.1093/nar/gkx1153. 911 supporting evidence. Nucleic Acids Res *46*, D1062-D1067. 10.1093/nar/gkx1153.
- 912 46. Landrum, M.J., Lee, J.M., Riley, G.R., Jang, W., Rubinstein, W.S., Church, D.M., and Maglott, D.R.<br>913 (2014). ClinVar: public archive of relationships among sequence variation and human phenotype. 913 (2014). ClinVar: public archive of relationships among sequence variation and human phenotype.<br>914 Mucleic Acids Res 42, D980-985. 10.1093/nar/qkt1113. 914 Nucleic Acids Res *42*, D980-985. 10.1093/nar/gkt1113.
- 915 47. Backman, J.D., Li, A.H., Marcketta, A., Sun, D., Mbatchou, J., Kessler, M.D., Benner, C., Liu, D., 916<br>916 Locke, A.E., Balasubramanian, S., et al. (2021). Exome sequencing and analysis of 454,787 UK 916 Locke, A.E., Balasubramanian, S., et al. (2021). Exome sequencing and analysis of 454,787 UK<br>917 Biobank participants. Nature 599, 628-634. 10.1038/s41586-021-04103-z. 917 Biobank participants. Nature *599*, 628-634. 10.1038/s41586-021-04103-z.
- 918 48. Jurgens, S.J., Choi, S.H., Morrill, V.N., Chaffin, M., Pirruccello, J.P., Halford, J.L., Weng, L.C., 919<br>919 Nauffal. V., Roselli, C., Hall, A.W., et al. (2022). Analysis of rare genetic variation underlying 919 Nauffal, V., Roselli, C., Hall, A.W., et al. (2022). Analysis of rare genetic variation underlying 920 cardiometabolic diseases and traits among 200,000 individuals in the UK Biobank. Nat Genet *54*, 921 240-250. 10.1038/s41588-021-01011-w.
- 922 49. Pilarski, R. (2019). PTEN Hamartoma Tumor Syndrome: A Clinical Overview. Cancers (Basel) *11*. 923 10.3390/cancers11060844.
- 924 50. Tischkowitz, M., Colas, C., Pouwels, S., Hoogerbrugge, N., Group, P.G.D., and European Reference<br>925 Network, G. (2020). Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour 925 Network, G. (2020). Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour<br>926 syndrome. Eur J Hum Genet 28, 1387-1393. 10.1038/s41431-020-0651-7. 926 syndrome. Eur J Hum Genet *28*, 1387-1393. 10.1038/s41431-020-0651-7.
- 927 51. Taliun, D., Harris, D.N., Kessler, M.D., Carlson, J., Szpiech, Z.A., Torres, R., Taliun, S.A.G., Corvelo, 928 (A., Gogarten, S.M., Kang, H.M., et al. (2021). Sequencing of 53.831 diverse genomes from the 928 A., Gogarten, S.M., Kang, H.M., et al. (2021). Sequencing of 53,831 diverse genomes from the 929 MHLBI TOPMed Program. Nature 590, 290-299. 10.1038/s41586-021-03205-y. 929 NHLBI TOPMed Program. Nature *590*, 290-299. 10.1038/s41586-021-03205-y.
- 930 52. Huang, L., Rosen, J.D., Sun, Q., Chen, J., Wheeler, M.M., Zhou, Y., Min, Y.-I., Kooperberg, C., 931 Conomos, M.P., Stilp, A.M., et al. (2022). TOP-LD: A tool to explore linkage disequilibrium with 931 Conomos, M.P., Stilp, A.M., et al. (2022). TOP-LD: A tool to explore linkage disequilibrium with<br>932 TOPMed whole-genome sequence data. The American Journal of Human Genetics 109, 1175-932 TOPMed whole-genome sequence data. The American Journal of Human Genetics *109*, 1175-1181. 933 10.1016/j.ajhg.2022.04.006.
- 934 53. Genetic effects on gene expression across human tissues. (2017). Nature *550*, 204-213. 935 10.1038/nature24277.
- 936 54. Butler, D.C., Petterson, S., Phillips, R.L., and Bazemore, A.W. (2013). Measures of social<br>937 deprivation that predict health care access and need within a rational area of primary care 937 deprivation that predict health care access and need within a rational area of primary care service<br>938 delivery. Health Serv Res 48, 539-559. 10.1111/j.1475-6773.2012.01449.x. 938 delivery. Health Serv Res *48*, 539-559. 10.1111/j.1475-6773.2012.01449.x.
- 939 55. Kimenai, D.M., Pirondini, L., Gregson, J., Prieto, D., Pocock, S.J., Perel, P., Hamilton, T., Welsh, P.,<br>940 Campbell, A., Porteous, D.J., et al. (2022). Socioeconomic Deprivation: An Important, Largely 940 Campbell, A., Porteous, D.J., et al. (2022). Socioeconomic Deprivation: An Important, Largely<br>941 **Campionia - Contant Antiche Depress** Circulation 146, 2 941 Unrecognized Risk Factor in Primary Prevention of Cardiovascular Disease. Circulation *146*, 240- 942 248. 10.1161/CIRCULATIONAHA.122.060042.
- 943 56. Schultz, W.M., Kelli, H.M., Lisko, J.C., Varghese, T., Shen, J., Sandesara, P., Quyyumi, A.A., Taylor,<br>944 H.A., Gulati, M., Harold, J.G., et al. (2018). Socioeconomic Status and Cardiovascular Outcomes: 944 H.A., Gulati, M., Harold, J.G., et al. (2018). Socioeconomic Status and Cardiovascular Outcomes:<br>945 Challenges and Interventions. Circulation 137, 2166-2178. 10.1161/CIRCULATIONAHA.117.0296 945 Challenges and Interventions. Circulation *137*, 2166-2178. 10.1161/CIRCULATIONAHA.117.029652.

- 946 57. Bann, D., Wright, L., Hardy, R., Williams, D.M., and Davies, N.M. (2022). Polygenic and<br>947 socioeconomic risk for high body mass index: 69 years of follow-up across life. PLoS Ge 947 socioeconomic risk for high body mass index: 69 years of follow-up across life. PLoS Genet *18*, 948 e1010233. 10.1371/journal.pgen.1010233.
- 949 58. Cromer, S.J., Lakhani, C.M., Mercader, J.M., Majarian, T.D., Schroeder, P., Cole, J.B., Florez, J.C.,<br>950 Patel, C.J., Manning, A.K., Burnett-Bowie, S.M., Merino, J., and Udler, M.S. (2023). Association and 950 Patel, C.J., Manning, A.K., Burnett-Bowie, S.M., Merino, J., and Udler, M.S. (2023). Association and 951 951 Interaction of Genetics and Area-Level Socioeconomic Factors on the Prevalence of Type 2<br>952 Diabetes and Obesity. Diabetes Care 46, 944-952. 10.2337/dc22-1954. 952 Diabetes and Obesity. Diabetes Care *46*, 944-952. 10.2337/dc22-1954.
- 953 59. Mostafavi, H., Harpak, A., Agarwal, I., Conley, D., Pritchard, J.K., and Przeworski, M. (2020).<br>954 Variable prediction accuracy of polygenic scores within an ancestry group. Elife 9. 954 Variable prediction accuracy of polygenic scores within an ancestry group. Elife *9*. 955 10.7554/eLife.48376.
- 956 60. He, Y., Qian, D.C., Diao, J.A., Cho, M.H., Silverman, E.K., Gusev, A., Manrai, A.K., Martin, A.R., and<br>957 **Patel, C.J. (2023).** Prediction and stratification of longitudinal risk for chronic obstructive pulmonary Patel, C.J. (2023). Prediction and stratification of longitudinal risk for chronic obstructive pulmonary 958 disease across smoking behaviors. medRxiv. 10.1101/2023.04.04.23288086.
- 959 61. Martin, A.R., Kanai, M., Kamatani, Y., Okada, Y., Neale, B.M., and Daly, M.J. (2019). Clinical use of 960 960 current polygenic risk scores may exacerbate health disparities. Nat Genet *51*, 584-591. 961 10.1038/s41588-019-0379-x.
- 962 62. Flegel, W.A. (2007). The genetics of the Rhesus blood group system. Blood Transfus *5*, 50-57. 963 10.2450/2007.0011-07.
- 964 63. Lee, Y.H., Thaweethai, T., Sheu, Y.H., Feng, Y.A., Karlson, E.W., Ge, T., Kraft, P., and Smoller, J.W.<br>965 (2023). Impact of selection bias on polygenic risk score estimates in healthcare settings. Psychol 965 (2023). Impact of selection bias on polygenic risk score estimates in healthcare settings. Psychol Med, 1-11. 10.1017/s0033291723001186.
- 967 64. Boutin, N., Mathieu, K., Hoffnagle, A., Allen, N., Castro, V., Morash, M., O'Rourke, P., Hohmann, E.,<br>968 Herring, N., Bry, L., et al. (2016). Implementation of Electronic Consent at a Biobank: An Opportunity 968 Herring, N., Bry, L., et al. (2016). Implementation of Electronic Consent at a Biobank: An Opportunity<br>969 for Precision Medicine Research. Journal of Personalized Medicine 6, 17. 10.3390/jpm6020017. 969 for Precision Medicine Research. Journal of Personalized Medicine *6*, 17. 10.3390/jpm6020017.
- 970 65. Goldstein, J.I., Crenshaw, A., Carey, J., Grant, G.B., Maguire, J., Fromer, M., O'Dushlaine, C., 971 Moran, J.L., Chambert, K., Stevens, C., et al. (2012). zCall: a rare variant caller for array-based 971 Moran, J.L., Chambert, K., Stevens, C., et al. (2012). zCall: a rare variant caller for array-based<br>972 genotyping: genetics and population analysis. Bioinformatics 28, 2543-2545. 972 genotyping: genetics and population analysis. Bioinformatics *28*, 2543-2545. 973 10.1093/bioinformatics/bts479.
- 974 66. Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990). Basic local alignment 975 975 search tool. J Mol Biol *215*, 403-410. 10.1016/s0022-2836(05)80360-2.
- 976 67. Das, S., Forer, L., Schonherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, S.I., Chew, E.Y., Levy,<br>977 S., McGue, M., et al. (2016). Next-generation genotype imputation service and methods. Nat Genet 977 S., McGue, M., et al. (2016). Next-generation genotype imputation service and methods. Nat Genet 978 978 *48*, 1284-1287. 10.1038/ng.3656.
- 979 68. Loh, P.R., Palamara, P.F., and Price, A.L. (2016). Fast and accurate long-range phasing in a UK<br>980 Biobank cohort. Nat Genet 48, 811-816. 10.1038/ng.3571. 980 Biobank cohort. Nat Genet *48*, 811-816. 10.1038/ng.3571.
- 981 69. Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, S.I., Chew, E.Y., Levy,<br>982 S., McGue, M., et al. (2016). Next-generation genotype imputation service and methods. Nature S., McGue, M., et al. (2016). Next-generation genotype imputation service and methods. Nature 983 Genetics *48*, 1284-1287. 10.1038/ng.3656.
- 984 70. Danecek, P., Auton, A., Abecasis, G., Albers, C.A., Banks, E., DePristo, M.A., Handsaker, R.E., 985 Lunter, G., Marth, G.T., Sherry, S.T., et al. (2011). The variant call format and VCFtools. Lunter, G., Marth, G.T., Sherry, S.T., et al. (2011). The variant call format and VCFtools. 986 Bioinformatics *27*, 2156-2158. 10.1093/bioinformatics/btr330.
- 987 71. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-<br>988 coneration PLINK: rising to the challenge of larger and richer datasets. Gigascience 4.7. 988 generation PLINK: rising to the challenge of larger and richer datasets. Gigascience *4*, 7. 989 10.1186/s13742-015-0047-8.
- 990 72. McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., 991 (15).<br>991 Martshuler, D., Gabriel, S., Daly, M., and DePristo, M.A. (2010). The Genome Analysis Toolkit: a Altshuler, D., Gabriel, S., Daly, M., and DePristo, M.A. (2010). The Genome Analysis Toolkit: a

- 992 MapReduce framework for analyzing next-generation DNA sequencing data. Genome research *20*, 993 1297-1303. 10.1101/gr.107524.110.
- 994 73. The Hail Team. Hail. https://github.com/hail-is/hail.
- 995 74. Conomos, M.P., Reiner, A.P., Weir, B.S., and Thornton, T.A. (2016). Model-free Estimation of 996 Recent Genetic Relatedness. Am J Hum Genet 98, 127-148. 10.1016/j.aihq. 2015.11.022. 996 Recent Genetic Relatedness. Am J Hum Genet *98*, 127-148. 10.1016/j.ajhg.2015.11.022.
- 997 75. Saitou, N., and Nei, M. (1987). The neighbor-joining method: a new method for reconstructing<br>998 bhylogenetic trees. Molecular Biology and Evolution 4.406-425. 998 phylogenetic trees. Molecular Biology and Evolution *4*, 406-425. 999 10.1093/oxfordjournals.molbev.a040454.
- 1000 76. Paradis, E., and Schliep, K. (2019). ape 5.0: an environment for modern phylogenetics and 1001 evolutionary analyses in R. Bioinformatics *35*, 526-528. 10.1093/bioinformatics/bty633.
- 1002 77. Zhou, Y., Browning, S.R., and Browning, B.L. (2020). A Fast and Simple Method for Detecting 1003 Identity-by-Descent Segments in Large-Scale Data. The American Journal of Human Genetics 106,<br>1004 426-437. 10.1016/j.ajhg.2020.02.010. 1004 426-437. 10.1016/j.ajhg.2020.02.010.
- 1005 78. Browning, S.R., and Browning, B.L. (2015). Accurate Non-parametric Estimation of Recent Effective<br>1006 Population Size from Segments of Identity by Descent. The American Journal of Human Genetics 97 1006 Population Size from Segments of Identity by Descent. The American Journal of Human Genetics *97*, 1007 404-418. 10.1016/j.ajhg.2015.07.012.
- 1008 79. McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R., Thormann, A., Flicek, P., and Cunningham,<br>1009 F. (2016). The Ensembl Variant Effect Predictor. Genome Biol 17, 122. 10.1186/s13059-016-0974-4. 1009 F. (2016). The Ensembl Variant Effect Predictor. Genome Biol *17*, 122. 10.1186/s13059-016-0974-4.
- 1010 80. Liu, X., Li, C., Mou, C., Dong, Y., and Tu, Y. (2020). dbNSFP v4: a comprehensive database of 1011 transcript-specific functional predictions and annotations for human nonsynonymous and splice-site 1012 SNVs. Genome Med *12*, 103. 10.1186/s13073-020-00803-9.
- 1013 81. Cingolani, P., Platts, A., Wang le, L., Coon, M., Nguyen, T., Wang, L., Land, S.J., Lu, X., and Ruden,<br>1014 D.M. (2012). A program for annotating and predicting the effects of single nucleotide polymorphisms. 1014 D.M. (2012). A program for annotating and predicting the effects of single nucleotide polymorphisms,<br>1015 ShpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 1015 SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) *6*, 80-92. 10.4161/fly.19695.
- 1017 82. Ge, T., Chen, C.Y., Ni, Y., Feng, Y.A., and Smoller, J.W. (2019). Polygenic prediction via Bayesian<br>1018 regression and continuous shrinkage priors. Nat Commun 10, 1776. 10.1038/s41467-019-09718-5. 1018 regression and continuous shrinkage priors. Nat Commun *10*, 1776. 10.1038/s41467-019-09718-5.
- 1019 83. Carroll, R.J., Bastarache, L., and Denny, J.C. (2014). R PheWAS: data analysis and plotting tools for<br>1020 http://en.co.ide.is.co.ide.is.co.ide.is.in.inc.is.in.inc.is.in.inc.is.in.inc.inc.inc.inc.inc.inc.inc.inc. 1020 phenome-wide association studies in the R environment. Bioinformatics *30*, 2375-2376. 1021 10.1093/bioinformatics/btu197.
- 1022 84. Yadlowsky, S., Hayward, R.A., Sussman, J.B., McClelland, R.L., Min, Y.-I., and Basu, S. (2018).<br>1023 Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic 1023 Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic 1024 Cardiovascular Disease Risk. Annals of Internal Medicine *169*, 20-29. 10.7326/M17-3011.
- 1025 85. van Buuren, S., and Groothuis-Oudshoorn, K. (2011). mice: Multivariate Imputation by Chained 1026 Equations in R. Journal of Statistical Software 45, 1 67. 10.18637/jss.v045.i03. 1026 Equations in R. Journal of Statistical Software *45*, 1 - 67. 10.18637/jss.v045.i03.
- 1027 86. Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J.A., Ziyatdinov, A., Benner, C., 1028<br>1028 C'Dushlaine. C., Barber, M., Boutkov, B., et al. (2021). Computationally efficient whole-genome 1028 O'Dushlaine, C., Barber, M., Boutkov, B., et al. (2021). Computationally efficient whole-genome<br>1029 regression for quantitative and binary traits. Nat Genet 53, 1097-1103. 10.1038/s41588-021-008 1029 regression for quantitative and binary traits. Nat Genet *53*, 1097-1103. 10.1038/s41588-021-00870-7.
- 1030 87. Bulik-Sullivan, B.K., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Patterson, N., Daly, M.J., Price, 1031 A.L., and Neale, B.M. (2015). LD Score regression distinguishes confounding from polygenicity in 1031 A.L., and Neale, B.M. (2015). LD Score regression distinguishes confounding from polygenicity in 1032 epenome-wide association studies. Nature Genetics 47, 291-295. 10.1038/ng.3211. 1032 genome-wide association studies. Nature Genetics *47*, 291-295. 10.1038/ng.3211.
- 1033 88. Brokamp, C., Wolfe, C., Lingren, T., Harley, J., and Ryan, P. (2018). Decentralized and reproducible<br>1034 ceocoding and characterization of community and environmental exposures for multisite studies. J 1034 geocoding and characterization of community and environmental exposures for multisite studies. J<br>1035 Am Med Inform Assoc 25, 309-314. 10.1093/jamia/ocx128. 1035 Am Med Inform Assoc *25*, 309-314. 10.1093/jamia/ocx128.

1036 89. Kulldorff, M. (1997). A spatial scan statistic. Communications in Statistics - Theory and Methods *26*, 1037 1481-1496. 10.1080/03610929708831995.



# Figure 2



## Figure 3



Figure 4



Figure 5



Figure S1



Figure S2



# Figure S3

a





Figure S4





UMAP1









